

**CURRICULUM VITAE****1. Personal Details**

Name: Shira Zelber-Sagi

Office Telephone Number: Tel: 972-4-8288675

Email Address: szelber-s@univ.haifa.ac.il

Personal Webpage: <http://hw.haifa.ac.il/en/people/sph/szelber-s>

Fax Number: Tel: 972-4-8288637

**2. Higher Education****A. Undergraduate and Graduate Studies**

<b>Period of Study</b>	<b>Name of Institution and Department</b>	<b>Degree</b>
1995- 1998	Nutrition Sciences in the Agriculture Faculty, Hebrew University	B.Sc
2001- 2007	Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel Aviv University	Ph.D. Direct

**B. Post-Doctoral Studies**

<b>Period of Study</b>	<b>Name of Institution and Department/Lab</b>	<b>Name of Host</b>
2008	Tel-Aviv Medical Center, Department of Gastroenterology and Hepatology	Prof. Ran Oren

**3. Academic Ranks and Tenure in Institutes of Higher Education**

<b>Years</b>	<b>Name of Institution and Department</b>	<b>Rank/Position</b>
10/2009-09/2013	School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa	Lecturer (50% position)
10/2013-01/2018	School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa	Senior Lecturer (with tenure, 100% position)
07-09/2015	Sabbatical at the School of Public Health, University of Georgia, Athens USA	Visiting Scholar
02/2018-06/2021	School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa	Associate Professor
2019-present	Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington	Courtesy appointment Affiliate

		Associate Professor
06/2021	School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa	Full Professor

Note: \* represents activities since the last appointment.

#### 4. Offices in University Academic Administration

Years	Name of Institution and Department	Role
2011	School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa	Responsible for the research committee
2013- 2019	School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa	Head of nutrition, health and behavior program
2013- 2014	School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa	Responsible for the Ph.D. forum
2014- present	School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa	Member of the Ph.D. committee
2014- 2019	School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa	Head of MA committee
2014- present	Research Center for the Evaluation of Health Promotion Interventions	Member
2015- present	Faculty of Social Welfare and Health Sciences University of Haifa	Member at the research committee
10/2019-present	Faculty of Social Welfare and Health Sciences University of Haifa	Head of School of Public Health
2020-2024	Faculty of Social Welfare and Health Sciences University of Haifa	Leading on behalf of the university the project Sharing European Educational Experience in Public Health for Israel (SEEEPHI) - a Capacity Building in Higher Education project funded through ERASMUS+

#### 5. Scholarly Positions and Activities outside the University

Years	Name of Institution and Department	Position
<b>Positions</b>		
1999- present	Tel-Aviv Medical Center	Dietitian and Researcher
1999- 2009	Clalit Healthcare Services	Dietitian and Group manager
1999-2001	"Mishan" Givataim Geriatric Institute	Manager of the nutrition unit
2006-2007	Clalit Health Services	Manager of the Internet nutrition forum
<b>Consultant</b>		
2009-2010	The Samuel Neaman Institute, the Technion	Researcher responsible for

		the construction of a long-term health promotion program for low socioeconomic population
<b>Committees</b>		
2012- present	The National Committee for Nutrition, Gastroenterology and Liver Disease, the Ministry of Health	Member
2014	Sub-committee aimed to reduce sugar intake in the Israeli population, on behalf of the Ministry of Health	Leading the writing of the position paper for sugar reduction
2014	Sub-committee, the Ministry of Health	Member Writing the nutritional guidelines for pregnancy
2014-2020	The Israeli Dietitians Society – ATID	Head of the “Gastroenterology and Hepatology Nutrition Forum”
2015-present	Ministry of Health	Member of a professional team developing the training program for expertise in nutrition for dietitians, led by the Ministry of Health
2016	MALAG (Council for Higher Education)	Member of a committee aimed at the approval of a new academic teaching program
2018	United European Gastroenterology (UEG) Digestive Health Summit and Austrian EU Presidency	Member of a committee aimed at food reformulation and options on how to limit the intake of processed food
2018-present	The European Association for the Study of the Liver (EASL)	Member in EASL Policy and Public Health Committee
2019-present	United European Gastroenterology (UEG)	Member of Policy and Public Health Committee
2020-2023	HEPAHEALTH II committee. EASL funded project in collaboration with Health Lumen	A mathematical modeling study quantifying the future epidemiological and economic burden of liver disease and the impact of interventions to reduce liver disease in Europe
2020	MALAG (Council for Higher Education)	Chair of a committee aimed at the approval of a new MA academic teaching program

2020-2023	Wilton Park in partnership with the EASL International Liver Foundation (EILF)	A member of the advisory board dealing with building a consensus for care pathways for NAFLD/NASH
2022	MALAG (Council for Higher Education)	A reviewer of a new BA academic teaching program
2022	MALAG (Council for Higher Education)	A reviewer of a follow-up report on the MA academic teaching program
2022-present	Global NASH Council <a href="https://www.globalnashcouncil.org/members/">https://www.globalnashcouncil.org/members/</a>	The leadership committee member. A co-chair of the "NAFLD Lifestyle" Committee and a member of the "NAFLD Policy, Public Health and Health Disparity Committee"
2023- present	The European Association for the Study of the Liver (EASL)	The EASL Governing Board member. Public Health Councillor-elect
<b>Writing Professional Position Statements and Clinical Guidelines</b>		
2014	Israeli Heart Society and the Israeli Dietitians Society– ATID	A member of the scientific team writing guidelines on nutrition for cardiovascular disease prevention
2016-2018	The Israeli Dietitians Society – ATID	A member of the team writing nutritional recommendations for patients with inflammatory bowel disease
2018	The Israeli Dietitians Society – ATID	A leading member of the scientific team writing a position paper on Nutritional recommendations for patients with non-alcoholic fatty liver disease (NAFLD)
2018	The European Association for the Study of the Liver (EASL)	A leading member of the scientific team writing policy statements on Obesity, nutrition, and NAFLD in Europe
2018	The European Association for the Study of the Liver (EASL)	A leading member of the scientific team of the EASL Clinical Practice Guidelines on nutrition in chronic liver disease
2020	Israeli Heart Society and the Israeli Dietitians Society– ATID	A member of the scientific team writing guidelines on

		nutrition for cardiovascular disease prevention (updated guidelines)
2020	United European Gastroenterology (UEG)	A leading member of the scientific team writing policy statement on Ultra-processed foods: an EU health crisis. Addressing unhealthy dietary patterns through mandatory front-of-pack labelling
2020	The European Association for the Study of the Liver (EASL)	A panel member of the EASL Clinical Practice Guidelines on NAFLD for Patients
2020	The European Association for the Study of the Liver (EASL)	A leading member of the scientific team writing policy statement on Food, alcohol and obesity: Policy Statement on the co-existence of Metabolic Associated Fatty Liver Disease (MAFLD) and Alcohol-related Fatty Liver Disease (AFLD)
2021-2023	American Society for Gastrointestinal Endoscopy (ASGE) and European Society for Gastrointestinal Endoscopy	A member of the scientific team of the ASGE ESGE Joint Clinical Practice Guidelines on Primary Endoscopic Bariatric & Metabolic Therapies
2021	The European Association for the Study of the Liver (EASL)	A DELPHI Panel member of the EASL revised Clinical Practice Guidelines on Liver Transplantation
2021	United European Gastroenterology (UEG) Public Affairs Committee	A member of the scientific team writing policy statement on: COVID-19 and Digestive Health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients doi: 10.1002/ueg2.12173.
2022-2024	The European Association for the Study of the Liver (EASL)	A panel member of the EASL Clinical Practice Guidelines

		for NAFLD
2023-	The Israeli Association for the Study of the Liver (IASL)	A member of the team for the Israeli Clinical Practice Guidelines for NAFLD
<b>Reviewing for Funding Agencies</b>		
2012-2016	Israel Science Foundation (ISF) Public Health Committee	Member review committee
2019	Israel National Institute for Health Policy Research (NIHP)	Reviewer
2021	Israel Science Foundation (ISF) Public Health Committee	Reviewer
2022	Chief Scientist Ministry of Health	Member of a review committee
<b>Editorial Assignments</b>		
2012-2014	<i>"Liver International"</i>	A member of the editorial board
2013-2015	<i>"World Journal of Gastroenterology"</i>	A member of the editorial board
2014	<i>"BioMed Research International"</i>	Guest Editor of a special topic "Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management"
2018-2020	<i>"Annals of Hepatology"</i>	A member of the editorial board
2020-	<i>"Journal of Hepatology"</i>	A member of the editorial board
2021-	<i>"Metabolism and Target Organ Damage (M&amp;TOD)"</i>	A member of the editorial board
2021-	<i>"Frontiers in Public Health and Nutrition"</i>	A member of the editorial board
2021-	<i>"EASL Studio"</i> <i>Recorded expert discussions around the latest news, techniques and advances in Hepatology</i>	A member of the editorial board
2022	<i>"Nutrients"</i>	Guest Editor of a special topic "Relationship between Diet and NAFLD: From Pathogenesis, Clinical and Epidemiological Studies to Prevention and Health Policy"
<b>Invited Academic Reviews</b>		
2016-present	Tel-Aviv University, School of Public Health	Invited reviewer for PhD and thesis works in epidemiology
2016-present	Tel-Hai College, Nutrition department	Invited reviewer for thesis works in nutrition
2019	Rambam Medical Center	Invited reviewer for a grant

		application to the "Ofakim" program
2023	Syddansk University Odense, Denmark	Invited reviewer (in-person exam)
2023	The Hebrew University	Invited reviewer for Ph.D. in nutrition sciences
<b>Ph.D. accompanying Committees</b>		
2021	Technion	Member
2021	The Hebrew University	Member
<b>Promotion Committees</b>		
2020	Ariel University	Invited reviewer for academic promotion
2020, 2023	Tel-Aviv University	Academic Promotion Committee member
2022	Ashkelon college, Public Health department	Academic Promotion Committee member
2022	Ariel University	Invited reviewer for academic promotion
<b>Reviewing for Refereed Journal</b>		
2007-present	Reviewer for international journals: International Scientific Journals such as: Gut (Q1), Hepatology (Q1), Journal of Hepatology (Q1), Liver International (Q1), Clinical Gastroenterology and Hepatology (Q1), World Journal Gastroenterology (Q2), Alimentary Pharmacology & Therapeutics (Q1), Public Health Nutrition (Q2), Nature Reviews Gastroenterology & Hepatology (Q1), Israel Journal of Health Policy Research (Q2), Lancet Gastroenterology & Hepatology (Q1)	
2018-2019	The European Association for the Study of the Liver (EASL)	Reviewer of abstracts selected for the annual international EASL conference
2019-present	Global Burden of Disease (GBD) collaborator	Reviewer for GBD papers and listed in the publications as a collaborator
<b>Memberships in Academic Professional Associations</b>		
2000- present	The Israeli Dietitians Association – ATID	
2002- present	The Israeli Association for the Study of the Liver	
2010- present	The European Association for the Study of the Liver (EASL)	
2012- 2015	The American Association for the Study of the Liver (AASLD)	
2022	The American Association for the Study of the Liver (AASLD)	
<b>Participation in International Educational Activities</b>		

2021	EASL-ESPEN Nutrition in liver disease online course: nutrition treatment for cirrhotic patient a case study
2021	EASL-ESPEN Nutrition in Liver Disease online course: The DNA of motivation in nutritional treatment
2022	ELPA (European Liver Patients' Association) Advisory Team member
<b>Participation in Local Educational Activities</b>	
2021	Israeli Medical Association Nutrition in Liver Disease online course: NAFLD
2021	Israeli Medical Association Nutrition in Liver Disease online course: Cirrhosis

## 6. Active Participation in Scholarly Conferences

### A1. International Conferences - Held Abroad

Date	Name of Conference	Place of Conference	Subject of Lecture/ Discussion /Comments /poster	Role
09/04	European Association for the Study of the Liver	Lisbon	The prevalence of primary nonalcoholic fatty liver disease (NAFLD) in the Israeli population and the association with biochemical and anthropometric measures.	Poster
10/04	American Association for the Study of Liver Diseases	Boston	A double-blind randomized placebo-controlled trial of Orlistat for the treatment of NAFLD.	Oral presentation
04/05	European Association for the Study of the Liver	Paris	Does weight loss improve liver histopathology in NAFLD?	Poster
11/05	American Association for the Study of Liver Diseases	San Francisco	1) Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI.	Poster
			2) Is NAFLD an independent predictor of the metabolic syndrome?	Poster
			3) Hyperinsulinemia is a predictor of elevated serum ALT levels even after adjustment for NAFLD and liver histology.	Poster
04/06	European Association for the Study of the Liver	Vienna	Serum ALT is not a reliable screening tool for NAFLD in the general population.	Poster



Date	Name of Conference	Place of Conference	Subject of Lecture/ Discussion /Comments /poster	Role
04/07	European Association for the Study of the Liver	Barcelona	Long-term nutritional intake and the risk for NAFLD; a population-based study.	Poster
11/07	American Association for the Study of Liver Diseases	Boston	Role of physical activity in NAFLD: A population-based study.	Poster
04/08	European Association for the Study of the Liver	Milan	A comparison between the hepatorenal ultrasound index and steatotest for the non-invasive quantification of liver steatosis.	Poster
04/09	European Association for the Study of the Liver	Copenhagen	1) Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A study in the general population.	Poster
			2) Discordance between three successive Fibroscan measurements mirrors the variability of liver fibrosis.	Poster
09/09	European Association for the Study of the Liver	Bologna	Effect of diet, exercise and anti-obesity drugs on NAFLD.	<b>Invited keynote speaker</b> and a speaker in a panel discussion
04/10	European Association for the Study of the Liver	Vienna	1) A comparison of fatty liver index with three non-invasive methods for the detection and quantification of liver steatosis: regular ultrasound, hepatorenal ultrasound index and steatotest.	Poster
			2) The hepatorenal ultrasound index is correlated with obesity, ALT, insulin and adipocytokines.	Poster
05/10	European Association for the Study of the Liver Clinical School of Hepatology	Torino	Case study: lifestyle modification in a patient with NAFLD.	<b>Invited speaker</b>
01/11	European Association for the Study of the	Nice	1) Comparison of FibroTest to other calculated scores for liver fibrosis as a screening for	Poster

Date	Name of Conference	Place of Conference	Subject of Lecture/ Discussion /Comments /poster	Role
	Liver		advanced NAFLD in the general population.	
			2) Is there an association between coffee consumption and NAFLD or NASH and fibrosis in a general adult population?	Poster
04/11	European Association for the Study of the Liver	Berlin	Incidence and regression rates of NAFLD in seven years follow up of a cohort from the general population.	Poster
09/11	University of Georgia Global Health Symposium	Athens, Georgia	Metabolic and clinical aspects of fructose, soft drinks, and obesity-related disorders.	<b>Invited speaker</b>
10/11	United European Gastroenterology Week	Stockholm	Lifestyle and diet: What evidence for impact on NAFLD progression?	<b>Invited speaker</b> and a judge in poster competition
04/12	European Association for the Study of the Liver	Barcelona	1) The effect of resistance training on NAFLD, a randomized clinical trial.	Oral presentation
			2) NAFLD independently predicts type-2 diabetes and pre-diabetes during 1 seven-year prospective follow-up.	Poster
			3) A phase-2, randomized, double blind, placebo-controlled trial of Aramchol for the treatment of NAFLD.	Poster
11/12	American Association for the Study of Liver Diseases	Boston	Elevated alanine transaminase predicts new onset of depression in employees undergoing health screening examinations.	Poster
04/13	European Association for the Study of the Liver	Amsterdam	Non-high density lipoprotein cholesterol independently predicts new onset of NAFLD in a 7-year prospective follow-up.	Poster oral presentation
09/13	10th International Liver Therapy Meeting	Barcelona	Lifestyle as a treatment for NAFLD.	<b>Invited keynote speaker</b>
04/14	European Association for	London	1) Future prospective in the treatment of obesity.	<b>Chairperson and a invited</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
	the Study of the Liver			<b>keynote speaker</b>
			2) Coffee does not prevent development of NAFLD but may delay fibrosis progression: a prospective cohort study in the general population.	Poster oral presentation
02/15	EASL Monothematic Conference: Microbiota, Metabolism and NAFLD European Association for the Study of the Liver	Innsbruck, Austria	1) The association between serum levels of uric-acid and Alanine aminotransferase in a population-based cohort.	Poster
			2) Serum levels of soluble advanced glycation-end products receptor are inversely related with liver fat in NAFLD patients.	Poster
			3) Differences in general health perception among patients with NAFLD and controls.	Poster
04/15	European Association for the Study of the Liver	Vienna	Tackling fatty liver disease with lifestyle measures.	<b>Invited keynote speaker</b>
10/15	United European Gastroenterology Week	Barcelona	Understanding the role of vitamins and trace elements.	<b>Chair a symposium and Invited speaker</b>
04/16	European Association for the Study of the Liver	Barcelona	Serum levels of endocannabinoids are independent risk factors for NAFLD	Poster
05/16	EASL Monothematic Conference: Metabolism and NAFLD	Riga	The role of macro and micronutrients in NAFLD.	<b>Invited keynote speaker</b>
09/16	Scuola Superiore di Catania (University of Catania)	Catania, Italy	1) Fatty liver disease – epidemiology, prognosis and hepatic and extra-hepatic implications.	<b>Invited speaker</b>
			2) Lifestyle treatment for NAFLD.	<b>Invited speaker</b>
			3) Sugar, non-caloric sweeteners and health implications.	<b>Invited speaker</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
11/16	American Association for the Study of Liver Diseases	Boston	1) Epidemiology of viral hepatitis E in Israel.	Poster
			2) Probiotics do not improve clinical outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial.	Poster
04/17	European Association for the Study of the Liver	Amsterdam	Multidisciplinary Hepatology, lifestyle treatment in NAFLD.	<b>Invited keynote speaker</b>
05/17	International Conference on Fatty Liver (ICFL2017)	Seville	Managing the low-risk patient, providing practical advice regarding diet and exercise – Nutritionist perspective.	<b>Invited keynote speaker and chair</b>
11/17	United European Gastroenterology Week	Barcelona	Nutrition and the liver.	<b>Invited keynote speaker</b>
04/18	European Association for the Study of the Liver	Paris	1) NAFLD – How to achieve weight loss.	<b>Invited speaker</b>
			2) EASL clinical practice guidelines (CPGs) for nutrition in chronic liver disease.	<b>Co-author</b>
06/18	AASLD/EASL NAFLD Endpoints Conference	Washington	Application of Lifestyle Management in Clinical Trials: Achieving Parity Across Sites.	<b>Invited keynote speaker</b>
09/18	EASL NAFLD summit	Geneva	Nutritional treatment in end-stage liver disease.	<b>Invited keynote speaker</b>
10/18	United European Gastroenterology Week	Vienna	Serum sRAGE levels are associated with unhealthy lifestyles and non-alcoholic fatty liver disease.	Oral presentation (won an excellence in research prize)
11/18	American Association for the Study of Liver Diseases	San-Francisco	Models for the prediction of cirrhosis in a dataset of the general population.	Poster
04/19	European Association for the Study of the Liver	Vienna	1) Assessment and relevance of sarcopenia and frailty.	<b>Invited keynote speaker</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
			2) Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD).	<b>Invited keynote speaker and chair</b>
			3) Meet the expert: exercise or diet, which is best for NAFLD patients.	<b>Invited keynote speaker</b>
06/19	Liver Seminars	Madrid	Lifestyle treatment in NAFLD	<b>Invited keynote speaker</b>
06/19	International Conference on Fatty Liver (ICFL2019)	Berlin	Lifestyle treatment in NAFLD.	<b>Invited speaker and chair</b>
09/19	EASL NAFLD summit	Seville	Lifestyle treatment in NAFLD.	<b>Invited speaker</b>
10/19	NASH leadership forum	Washington D.C.	Lifestyle treatment in NAFLD.	<b>Invited speaker and forum member</b>
10/19	United European Gastroenterology Week	Barcelona	1) High intake of phenolic acid is associated with a reduced risk of colorectal adenomas among smokers.	Oral presentation (presented by a graduate PhD student)
			2) Vitamin E and C intake is inversely associated with liver damage in patients with NAFLD.	Poster
			3) Dietary intake of phenolic acids is inversely associated with liver steatosis and insulin resistance in the general population.	Poster
			4) Meat intake and colorectal polyps.	Poster
11/19	European Workshop on NASH in Clinical Practice	Barcelona	How to implement lifestyle treatment in NAFLD.	<b>Invited speaker and chair</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
04/20 cancelled due to the pandemic and moved to an online conference	NAFLD/ NASH: the silent epidemic in collaboration with the EASL International Liver Foundation	Wilton-park London	Policy to tackle NAFLD	<b>Invited speaker and chair</b>
04/20 cancelled due to the pandemic	European Association for the Study of the Liver	London	1) Post Graduate Course – treatment of NAFLD	<b>Invited speaker</b>
			2) Debate on processed food	<b>Invited speaker</b>
			3) NAFLD management in multidisciplinary approach	<b>Chair</b>
09/20 due to the pandemic moved to an online conference	European Health Forum Gastein 2020	zoom	Alcohol, sugar and obesity: Synergies between risk factors and impact on liver disease	<b>Invited speaker</b>
10/20 due to the pandemic moved to an online conference	United European Gastroenterology Week	zoom	Obesity epidemiology and consequences	<b>Invited speaker</b>
11/20 due to the pandemic set as an online conference	European Association for the Study of the Liver- Patients Organizations forum	zoom	The synergism between obesity, sugar and alcohol in liver disease policy statement	<b>Invited speaker</b>
12/20 due to the pandemic set as an online conference	NAFLD/ NASH: the silent epidemic in collaboration with the EASL International Liver Foundation	Zoom	Policy strategies to address NAFLD	<b>Invited speaker and roundtable discussion</b>
04/21	4th Global NASH Congress	Zoom	From nutritional epidemiology to practical nutritional treatment in NAFLD	<b>Keynote speaker</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
06/21	European Association for the Study of the Liver	Zoom	1) NAFLD and diet	<b>Keynote speaker and roundtable discussion</b>
		Zoom	2) Multidisciplinary team approach for the treatment of liver diseases	<b>Keynote speaker and roundtable discussion</b>
06/21	Journal of Internal Medicine NAFLD Digital Meeting	Zoom	Dietary interventions and nutrition in NAFLD	<b>Keynote speaker</b>
07/21	The Nutrition Society UK Annual Conference	Zoom	More than weight reduction: nutritional approaches for the treatment of NAFLD	<b>Keynote speaker</b>
07/21	International Association for the Study of the Liver (IASL) Annual Conference	Zoom	Nutritional Interventions for NAFLD in the West	<b>Keynote speaker</b>
09/21	Conference on Liver Disease in Africa (COLDA) 2021	Zoom	Dietary treatment in NAFLD	<b>Keynote speaker</b>
09/21	European Society for Organ Transplantation (ESOT)	Milan	Managing 'Sarco-frailty' in the real world: How to prepare our patients	<b>Invited Keynote speaker</b>
09/21	European Association for the Study of the Liver NASH Summit	Zoom	What is the evidence supporting use of specific dietary patterns?	<b>Keynote speaker</b>
10/21	United European Gastroenterology Week	Zoom	1) Current concepts: The role of processed foods and lifestyle	<b>Keynote speaker</b>
			2) Treatment for NAFLD by lifestyle	<b>Keynote speaker</b>
10/21	European Congress of Dietetics The European	Zoom	Clinical Nutrition, fatty liver, obesity, metabolic diseases	<b>Speaker</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
	Federation of the Associations of Dietitians (EFAD)			
11/21	American Association for the Study of Liver Diseases	California US (turned to virtual)	Dietary intervention in Fatty liver disease	<b>Invited Keynote speaker</b>
05/22	Innovations in NAFLD care	Barcelona	Nutritionists' Perspective: Lifestyle and Behavioral Structured Interventions	<b>Invited Keynote speaker, chair and roundtable discussion panel member</b>
06/22	European Association for the Study of the Liver	London	1) Socioeconomic inequalities in metabolic, alcoholic and viral liver diseases	<b>Invited Keynote speaker, and roundtable discussion panel member</b>
			Is there an optimal lifestyle approach in NAFLD?	<b>Organizer and chair</b>
09/22	European Association for the Study of the Liver NASH Summit	Dublin	Nutrition, alcohol, and environmental toxins as (co-) factors of NAFLD	<b>Invited Keynote speaker</b>
10/22	United European Gastroenterology Week	Vienna	Nutritional evaluation and treatment of cirrhotic patient	<b>Invited Keynote speaker</b>
			Meat consumption and PNPLA3 polymorphism are associated with fatty liver in a multi-center cross-sectional study	Oral presentation



<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
			Case study of management NAFLD	<b>Roundtable discussion panel member</b>
10/22	MIRCIM 2022 McMaster International Review Course in Internal Medicine	Kraków	Non-alcoholic fatty liver disease: practical tips for diagnosis, treatment and prevention	<b>Invited Keynote speaker</b>
11/22	NASH council conference	Washington DC	Social Inequalities and diet in relation to NAFLD	<b>Invited speaker</b>
03/23	Liver Connect- Chronic Liver Disease Foundation annual conference	Huntington	Lifestyle Intervention Diet & Exercise	<b>Invited speaker</b>
03/23	MASTERCASS ABBVIE annual conference of the Spanish Association for the Study of the liver AEEH	Madrid	Public health policies in NAFLD	<b>Invited speaker</b>
04/23	Spanish Society of Diabetes XXXIV Annual Congress of the Spanish Society of Diabetes	Valencia	The link between Ultra Processed food and type-2 diabetes and NAFLD	<b>Invited Keynote speaker</b>
05/23	Innovations in NAFLD care	Barcelona	A debate on red meat intake and implications on liver health.	<b>Invited Keynote speaker, chair and roundtable discussion panel member</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
06/23	European Association for the Study of the Liver	Vienna	Lifestyle treatment for the cirrhotic patients by multidisciplinary team	<b>Chair and session organizer</b>
			Treatment of the lean NAFLD patients	<b>Invited panel member</b>
			Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study	<b>Invited speaker</b>
10/23	United European Gastroenterology Week	Copenhagen	Is lifestyle therapy effective in the management of MASLD?	<b>Invited Keynote speaker</b>
			Healthy Lifestyle Index is related with MASLD	<b>Oral presentation (presented by my PhD student)</b>
11/23	Global NASH Council (GNC) Meeting	Boston	Lifestyle interventions for the high risk MASLD patients	<b>Invited Keynote speaker</b>

## **A2. International Conferences - Held in Israel**

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
11/18	The epidemic of fatty liver disease Hadassah Medical Center	Jerusalem	NAFLD is a lifestyle-oriented and treated disease	<b>Invited keynote speaker</b>
11/18	The Israeli Association for	Tel-Aviv	Lifestyle treatment of NAFLD	<b>Invited keynote</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
	the Study of the Liver			<b>speaker</b>
11/19	Medicine 2040	Tel-Aviv	Fatty Liver: the cause of all troubles	<b>Invited keynote speaker</b>

### **A3. Local Conferences**

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
12/02	The Israeli Association for the Study of the Liver	Eilat	Role of noninvasive tests in the classification of nonalcoholic fatty liver disease (NAFLD).	Oral presentation
02/03	The Israeli Gastroenterology Association	Haifa	Factors modulating serum alanine aminotransferase (ALT) in patients with NAFLD.	Oral presentation
06/04	The Israeli Gastroenterology Association	Herzliya	Double-blind randomized placebo-control trial of Orlistat, for the treatment of primary NAFLD.	Oral presentation
06/04	The Israeli Association for the Research and Treatment of Obesity	Tel-Aviv	Double-blind randomized placebo-control trial of Orlistat, for the treatment of primary NAFLD.	Oral presentation
02/05	The Israeli Association for the Study of the Liver	Eilat	Is NAFLD an independent predictor of the metabolic syndrome?	Oral presentation
03/06	The Israeli Association for the Study of the Liver	Eilat	NAFLD and hyperinsulinemia are major determinants of serum ferritin levels.	Oral presentation
12/07	The Israeli Gastroenterology Association	Tiberias	Role of physical activity in NAFLD: A population-based study.	Oral presentation
03/08	The Israeli Association for the Study of the Liver	Eilat	A comparison between the hepatorenal ultrasound index and steatotest for the non-invasive quantification of liver steatosis.	Oral presentation
03/09	The Israeli Association for the Study of the Liver	Kfar Blum	Discordance between three successive Fibroscan measurements mirrors the variability of liver fibrosis.	Oral presentation
03/10	The Israeli Association for the Study of the Liver	Kfar Blum	A comparison of fatty liver index with three non-invasive methods for the detection and quantification of liver steatosis.	Oral presentation

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
03/12	The Israeli Association for the Study of the Liver	Kfar Blum	1) The effect of resistance training on NAFLD in a randomized clinical trial.	Oral presentation
			2) NAFLD independently predicts pre-diabetes during 1 seven-year prospective follow-up.	Oral presentation
05/12	Faculty of Medicine, Tel-Aviv University	Tel-Aviv	The effect of resistance training on NAFLD, a randomized clinical trial.	Poster
06/13	The Israeli Association for the Study of the Liver	Eilat	Non-HDL cholesterol as an independent predictor for NAFLD.	Oral presentation
06/14	The Israeli Association for the Study of the Liver	Eilat	Coffee does not prevent the development of NAFLD in a prospective cohort but may decrease fibrosis.	Poster
12/14	The 30 <sup>th</sup> Annual Meeting of the Israeli Society for Oxygen and Free Radicals Research	Ramat-Gan	Role of Advanced Glycation End Products-AGEs in NAFLD.	<b>Invited speaker</b>
06/15	The Israeli Association for the Study of the Liver	Eilat	Lifestyle in the treatment of NAFLD.	<b>Invited speaker</b>
02/16	The Israeli Gastroenterology Association	Tel-Aviv	1) Debate on artificial sweeteners and health outcomes.	<b>Invited speaker</b>
			2) Update on NAFLD	<b>Invited speaker</b>
06/16	The Israeli Association for the Study of the Liver	Eilat	1) Probiotics do not improve clinical outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial.	Poster
			2) Inadequate protein intake following laparoscopic sleeve gastrectomy surgery is associated with greater fat-free mass loss.	Poster
			3) Nutritional status prior to Laparoscopic Sleeve	Poster

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
			Gastrectomy surgery.	
11/16	The Israeli Association for the Study of the Liver	Tel-Aviv	A practical guide for lifestyle modification in NAFLD.	<b>Invited speaker</b>
06/17	The Israeli Association for the Study of the Liver	Eilat	Meat type and preparation method are associated with NAFLD.	Oral presentation
12/17	Family physicians conference on Gastroenterology	Galilei	The nutritional treatment of NAFLD.	<b>Invited speaker and chair</b>
02/18	Family Physicians Conference on Gastroenterology	Jerusalem	The nutritional treatment of NAFLD.	<b>Invited speaker</b>
05/18	Preventive nutrition conference	Tel-Aviv	Science, research, and nutrition; being the opinion leaders.	<b>Invited speaker and chair</b>
12/18	Leadership in nutrition, the Israeli Ministry of Health	Tel Hashomer	From research to practice: healthy diet and cooking methods in the prevention of aging.	<b>Invited speaker</b>
12/18	Family Physicians Conference on Gastroenterology	Herzliya	Health implications of processed food and	<b>Invited speaker</b>
01/19	Nutrition Medical Conference	Tel-Aviv	New Nutritional Lifestyle Treatments in NAFLD	<b>Invited speaker and chair</b>
06/19	The Israeli Association for the Study of the Liver	Eilat	Update of NAFLD	<b>Invited speaker and chair</b>
10/21	The Israeli Association for the Study of the Liver	Caesarea	Session: Obesity and fatty liver disease	Chair
			1) High meat consumption is prospectively associated with non-alcoholic fatty liver disease and liver fibrosis markers	Oral presentation (with PhD student)
			2) Serum sRAGE and dietary AGEs levels are prospectively associated with non-alcoholic fatty liver disease	Oral presentation (with PhD student)
12/21	The Israeli Association for the	Tel-Aviv	Nutritional approach in the treatment of NAFLD	<b>Invited speaker</b>

<b>Date</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Lecture/ Discussion /Comments /poster</b>	<b>Role</b>
	Study of Obesity			
05/22	The Israeli Association for the Study of the Liver	Zikhron	A case study analysis and NAFLD nutritional treatment update	<b>Invited speaker</b>
09/22	The Israeli Association for the Study of the Liver	Caesarea	Environmental exposures and NAFLD	<b>Invited speaker</b>
11/22	The Israeli Association for Endocrinology	Haifa	Environmental exposures – How to treat NAFLD in 2022?	<b>Invited speaker</b>
09/23	The Israeli Association for the Study of the Liver	Caesarea	A case study analysis and NAFLD nutritional treatment update	<b>Invited speaker</b>

**b. Organization of Conferences or Sessions**

<b>Year</b>	<b>Name of Conference</b>	<b>Place of Conference</b>	<b>Subject of Conference</b>	<b>Role</b>
11/08	The Israeli Dietitians Association – ATID professional conference	Herzliya, Israel	Updates in nutrition.	Chairperson, organizer, and head of committee assembling position statement on behalf of ATID
01/10	Nutrition Medical Conference	Tel-Aviv, Israel	Nutritional treatment for liver diseases.	Chairperson and organizer
05/11	International Olive Oil Conference TERRAOLIVO	Jerusalem, Israel	Olive oil and health, scientific session.	Chairperson and organizer
09/12	The Israeli Dietitians Association – ATID professional conference	Shfaim, Israel	Updates in nutrition.	Chairperson and a member of the steering committee.
12/12	School of Public Health, University of Haifa	Haifa, Israel	Childhood obesity, ethical and research aspects.	Chairperson and a member of the steering committee
01/14	Nutrition Medical Conference	Tel-Aviv, Israel	Microbiota and gastrointestinal and liver diseases.	Chairperson and organizer
09/14	The Israeli Dietitians Association – ATID professional conference	Ramat-Gan, Israel	Gastroenterology forum.	Chairperson and organizer
10/15	The Israeli Dietitians Association – ATID	Ramat-Gan, Israel	New topics in gastroenterology.	Chairperson and organizer

Year	Name of Conference	Place of Conference	Subject of Conference	Role
	professional conference			
05/16	Preventive nutrition	Tel-Aviv, Israel	Gut microbiota and health.	Chairperson
09/16	The Israeli Dietitians Association – ATID professional conference	Ramat-Gan, Israel	Dietary treatment for cirrhosis and inflammatory bowel disease.	Chairperson and organizer
05/17	Preventive nutrition	Tel-Aviv, Israel	Nutritional psychotherapy.	Chairperson and organizer
06/17	The Israeli Ministry of Health conference	Ramat-Gan, Israel	Mediterranean diet	Chairperson and organizer
11/17	The Israeli Dietitians Association – ATID professional conference	Ramat-Gan, Israel	From bedside to evidence-based guidelines in gastroenterology	Chairperson and organizer
05/18	Preventive nutrition	Tel-Aviv, Israel	Science, research and nutrition	Scientific chair of the conference.
11/18	The epidemic of fatty liver disease Hadassah Medical Center	Jerusalem, Israel	The epidemic of fatty liver diseases: risk factors, treatment and extrahepatic consequences	Scientific chair of the conference.
05/19	Preventive nutrition	Tel-Aviv, Israel	Personal nutrition approach	Chairperson and organizer.
11/19	European Workshop on NASH in Clinical Practice	Barcelona	NASH in Clinical Practice	Member of the organizing committee
03/20	The scientific basis of preparedness for Corona and other pandemics, the role of Schools of Public Health	University of Haifa	School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa hosted representatives of all Schools of Public Health in Israel, the Israeli Association of Public Health Physicians, and experts from other disciplines to have a discussion on	Organizer and chair

Year	Name of Conference	Place of Conference	Subject of Conference	Role
			preparedness and implications of the Corona pandemic, and the role of Schools of Public Health and academy	
04/20	European Association for the Study of the Liver	London	The annual conference of the EASL	Member of the organizing committee of the Public Health sessions. (The conference was canceled due to the Corona pandemic)
04/20	NAFLD/ NASH: the silent epidemic in collaboration with the EASL International Liver Foundation	Wilton Park London	This event brings together experts, thought leaders, practitioners, industry executives and high-level government officials from various disciplines and sectors to engage in solution-oriented dialogue	Member of the organizing committee (was moved to online conference due to the Corona pandemic)
01/21	Israeli research in different aspects of the Covid-19 pandemic	University of Haifa - Zoom	Original research on COVID-19 in the School of Public Health	Organizer and chair
03/21	Lessons and Opportunities in food security	Zoom	Multidisciplinary, policy discussion in food security	Member of the organizing committee and member of the panel discussion
05/22	The annual conference Schools of Public Health in Israel, the Israeli Association of Public Health Physicians	Ashkelon college	The future of public health in a changing world	Member of the organizing committee
05/22	Innovations in NAFLD care	Barcelona	New approach for managing NAFLD	Member of the organizing



Year	Name of Conference	Place of Conference	Subject of Conference	Role
				committee
05/22	Preventive nutrition	Tel-Aviv, Israel	(1) Nutritional psychotherapy (2) Nutrition is academic	Chairperson and organizer
07/22	Bioethics of human research	Haifa, Israel	Bioethics and public health	Organizer
02/23	The Theory meets practice. The conference of Schools of Public Health and Public Health Services of the Ministry of Health	University of Haifa	In practice – community studies performed by Schools of Public Health and Ministry of Health	Conference chair and organizer
05/23	Innovations in NAFLD care	Barcelona	New approach for managing NAFLD	Member of the organizing committee
06/23	Annual conference of The Association of Public Health Physicians in Israel	University of Haifa	Health in the Era of the "New Normal"	Conference chair and organizer

### 7. Invited Addresses

Year	Name of Forum	Place of Lecture	Subject of Lecture	Role
09/00	Geriatric medical Conference	Tel-Aviv, Israel	Physical activity and nutrition for the elderly.	Invited speaker
01/03	The Israeli Organization of Medical Laboratories	Tel-Aviv, Israel	Biochemical aspects and pathogenesis of Nonalcoholic fatty liver disease (NAFLD).	Invited speaker
02/03	Nutrition Medical Conference	Tel-Aviv, Israel	NAFLD - a new old disease.	Invited speaker

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Subject of Lecture</b>	<b>Role</b>
04/03	The Israeli Family Physicians Association Conference	Eilat, Israel	NAFLD prevalence and treatment.	Invited speaker
07/03	A pediatric conference in the Tel Aviv Medical Center	Tel-Aviv, Israel	NAFLD in children.	Invited speaker
09/04	The Israeli Association for the Study of the Liver	Herzliya, Israel	The epidemiology of primary NAFLD in Israel.	Invited speaker
01/05	Nutrition Medical Conference	Tel-Aviv, Israel	The metabolic syndrome, MABAT from the liver.	Invited speaker
11/05	Nutrition Medical Conference of Clalit Health Services	Tel-Aviv, Israel	The nutritional treatment of NAFLD.	Invited speaker
02/06	Nutrition Medical Conference	Ramat-Gan, Israel	Vitamins and minerals in human health.	Invited speaker
08/07	Nutrition Medical Conference of Clalit Health Services	Raanana, Israel	Pediatric NAFLD.	Invited speaker
11/07	Conference by "Hets"–The Israeli association for patients with liver diseases	Tel-Aviv, Israel	Nutritional management in liver diseases.	Invited speaker
05/08	Nurses conference by "Schering-Plough"	Tel-Aviv, Israel	The association between viral hepatitis B & C and insulin resistance.	Invited speaker
05/08	Nutrition Medical Conference	Tel-Aviv, Israel	What's between probiotics and NAFLD.	Invited speaker
11/08	Nutrition Medical Conference	Herzliya, Israel	The association between egg consumption and cardiovascular disease - Evidence-Based Medicine.	Invited speaker
05/09	Nutrition Medical Conference of Clalit Health Services	Raanana, Israel	The Association between soft drinks and obesity, NAFLD and diabetes.	Invited speaker
09/09	The Israeli Association for the Study of the Liver	Ramat-Gan, Israel	Effect of diet, Exercise and anti-obesity drugs on NAFLD.	Invited speaker
01/10	Nutrition Medical Conference	Tel-Aviv, Israel	Update in diet and physical activity for the treatment of NAFLD.	Invited speaker

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Subject of Lecture</b>	<b>Role</b>
02/10	Nutrition Medical Conference of Carmel Hospital	Haifa, Israel	Nutrition in viral liver disease and cirrhosis.	Invited speaker
05/11	International Olive Oil Conference TERRAOLIVO	Jerusalem, Israel	Effect of olive oil in The Liver.	Invited speaker
09/12	The Israeli Dietitians Association – ATID professional conference	Shfaim Israel	The association between probiotics and liver diseases.	Invited speaker
10/12	Nutrition Medical Conference of Clalit Health Services	Wohl-center Israel	The nutritional treatment of liver diseases.	Invited speaker
10/13	Tnuva Research institute	Herzliya, Israel	Metabolic and clinical aspects of sugar and fructose.	Invited speaker
06/14	The Israeli Family Physicians Association Conference	Ramat-Gan, Israel	The nutritional treatment of liver diseases.	Invited speaker
09/14	The Israeli Dietitians Association – ATID professional conference	Ramat-Gan, Israel	The dual association Between type-2 Diabetes and NAFLD.	Invited speaker
11/15	Family physicians conference on “debates in the treatment and management of gastrointestinal diseases”	Herzliya, Israel	Debate on artificial sweeteners and health outcomes.	Invited speaker
07/16	Family Physicians Conference on Gastroenterology	Herzliya, Israel	Fast food, health and policy.	Invited speaker
11/16	The Israeli Association for the Study of the Liver	Ramat-Gan, Israel	The nutritional treatment of NAFLD.	Invited speaker
02/17	National annual Ministry of Health conference	Shoham, Israel	Perspectives on sugar and salt.	Invited speaker
06/17	The National Council of Gastroenterology, Hepatology and Nutrition	Ramat-Gan, Israel	The Mediterranean Diet and metabolic benefits.	Invited speaker

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Subject of Lecture</b>	<b>Role</b>
11/18	EU parliament on behalf of the United European Gastroenterology (UEG) Digestive Health Summit	Brussels	The harmful effects of processed meat and added sugar on NAFLD	Invited speaker
12/18	Cholestatic liver disease patients conference	Tel-Aviv, Israel	Nutrition for liver disease	Invited speaker
05/19	ELPA- European Liver Patient Association	Zagreb, Croatia,	Nutrition for liver disease	Invited speaker
09/19	The Israeli Dietitians Association – ATID professional conference	Ramat-Gan, Israel	New and future directions in nutrition and physical activity for liver disease	Invited speaker
12/19	United European Gastroenterology (UEG) associations	Vienna	Food labeling in The context of gastrointestinal diseases	Invited speaker
01/21	The Forum for Sustainable Nutrition and the Nature Museum	Zoom	Expert panel on soft drinks damage and cola industry	Panel member
04/21	EU parliament on behalf of the United European Gastroenterology (UEG) association	Zoom	Understanding the Human Microbiome: The impact of ultra-processed foods	Speaker
06/21	The Croatian Society for Liver Diseases "Hepatos"	Zoom	Liver Cancer and diet	Speaker
06/21	European liver patient association (ELPA) NASH Symposium	Zoom	NAFLD and lifestyle	Speaker
12/21	European Parliament and the EASL and the Lancet press conference	Brussels (turned to virtual)	Protecting the next generation of Europeans against liver disease complications and premature mortality	Invited speaker

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Subject of Lecture</b>	<b>Role</b>
10/22	European liver patient association (ELPA) NASH Symposium	Zoom	Eating habits of children – are we on the right path?	Speaker
11/23	European liver patient association (ELPA) stakeholders meeting	Zoom	The EASL public health activities, present and future	Speaker

### 8. Colloquium Talks

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Presentation</b>
11/02	Dept. of Nursing, Tel Aviv University	Tel-Aviv, Israel	Clinical and nutritional aspects of NAFLD.
06/04	Maccabi Healthcare Course for Family Physicians	Ramat-Gan, Israel	Case studies in NAFLD.
05/06	Nutrition trainee's course, National Training Center, Ministry of Health	Tel-Hashomer, Israel	Nutritional management in NAFLD.
10/08	Nutrition seminar of Clalit Health Services	Tel-Aviv, Israel	Nutritional treatment for cirrhosis.
12/08	A conference for physicians from Eastern Europe, Tel Aviv Medical Center	Tel-Aviv, Israel	Nutrition in the pathogenesis and treatment of NAFLD.
05/09	Nutrition conference, Clalit Health Services	Raanana, Israel	Soft drinks consumption and obesity and NAFLD.
03/10	Gastroenterology course for medical students at the Tel-Aviv University (the 4 years program)	Tel-Aviv, Israel	Nutrition in the pathogenesis and treatment of NAFLD.
07/10	A conference for physicians from Kazakhstan at the Tel Aviv Medical Center	Tel-Aviv, Israel	Nutrition in the pathogenesis and treatment of NAFLD.
07/10	Nutrition seminar of Maccabi Healthcare	Ramat-Hasharon, Israel	Role of nutrition in liver and cardiovascular disease.

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Presentation</b>
10/10	Health promotion course for 6th year medical students at the Tel-Aviv University	Tel-Aviv, Israel	Nutrition and obesity in view of public health and primary prevention.
03/11	Gastroenterology course for medical students at the Tel-Aviv University (the 4 years program)	Tel-Aviv, Israel	Nutrition in the pathogenesis and treatment of NAFLD.
02/13	Institute for Endocrinology and Diabetes, at Schneider Children's Medical Center	Petah Tikva, Israel	Nutrition in the pathogenesis and treatment of pediatric NAFLD.
06/13	The Israeli Dietitians Association – ATID gastroenterology course	Rehovot, Israel	Nutritional treatment of liver disease and cirrhosis.
07/13	Nutritional treatment of diabetes course	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
02/14	Health promotion seminar of Maccabi Healthcare	Tel-Aviv, Israel	Nutritional epidemiology.
02/14	Nutritional treatment of diabetes course	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
03/14	The Israeli Dietitians Association – ATID gastroenterology course	Rehovot, Israel	Nutritional treatment of liver disease and cirrhosis.
03/14	MSD workers	Tel-Aviv, Israel	Supportive nutritional treatment in viral hepatitis
06/14	The Weizmann Institute of Science-metabolic seminar	Rehovot, Israel	Epidemiological research in NAFLD.
07/14	Nutritional treatment of diabetes course	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
02/15	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
02/15	Nutrition seminar of Clalit Health Services	Petah Tikva, Israel	Nutrition in the pathogenesis and treatment of NAFLD.

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Presentation</b>
05/15	The Israeli Dietitians Association – ATID gastroenterology course	Rehovot, Israel	Nutritional treatment of liver disease and cirrhosis.
07/15	NIH – National Institute of Health	Bethesda	Epidemiological and nutritional research in NAFLD.
09/15	The Georgia University, nutrition seminar	Athens, Georgia	BMI and mortality; the obesity paradox.
02/16	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
06/16	The Israeli Dietitians Association – ATID gastroenterology course	Tel-Aviv, Israel	Nutritional treatment of liver disease and cirrhosis.
10/16	Zagreb University, School of Medicine	Zagreb, Croatia	NAFLD – epidemiology, prognosis, and hepatic and extra-hepatic implications.
02/17	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
06/17	The Israeli Dietitians Association – ATID gastroenterology course	Tel-Aviv, Israel	Nutritional treatment of liver disease and cirrhosis.
12/17	Maccabi Healthcare seminar for dietitians	Tel-Aviv, Israel	Practical principles in the nutritional treatment of NAFLD.
12/17	Diabetes nurses' course at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD –hepatic and extra-hepatic implications and nutritional treatment.
02/18	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD and diabetes mellitus.
05/18	Preventive nutrition conference	Tel-Aviv, Israel	Nutritional epidemiology.
05/18	Zagreb University, School of Medicine	Zagreb, Croatia	NAFLD – epidemiology, prognosis, and hepatic and extra-hepatic implications.

<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Presentation</b>
05/18	Diabetes Educators course, The Ministry of Health	Tel-Hashomer, Israel	NAFLD and diabetes, inter-relationships and implications on treatment
07/18	Gastroenterology and hepatology meeting	Jerusalem, Israel	Nutritional treatment of liver cirrhosis, the new EASL guidelines.
09/19	Elimination Leaders Preceptorships-international workshop	Tel-Aviv, Israel	Holistic approach for treating liver diseases?
09/19	Swiss Association for the Study of the Liver (SASL)	SASL School of Hepatology webinar	Nutrition for the treatment of NAFLD.
12/19	Diabetes nurses' course, at the Tel-Aviv University	Tel-Aviv, Israel	NAFLD –hepatic and extra-hepatic implications and nutritional treatment.
03/20	Swiss Association for the Study of the Liver (SASL)	SASL School of Hepatology webinar	Lifestyle for the treatment of cirrhosis.
06/20	The Israeli Dietitians Association – ATID gastroenterology course	Webinar, Israel	Nutritional treatment of liver disease and cirrhosis.
10/20	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Webinar, Israel	NAFLD and diabetes mellitus.
01/21	Diabetes nurses' course at the Rambam Health Care Campus	Webinar, Israel	NAFLD and diabetes, inter-relationships and implications on treatment.
09/21	Internal Medicine Grand Rounds	University of Manitoba Canada, Virtual	Lifestyle and NAFLD; evidence and clinical implications.
10/21	Gut roundtable	Virtual, UK (GUT is Q1 Gastroenterology journal)	Current therapy and future directions in NASH.
10/21	Nutritional treatment of diabetes course for dietitians, at the Tel-Aviv University	Webinar, Israel	NAFLD and diabetes mellitus.



<b>Year</b>	<b>Name of Forum</b>	<b>Place of Lecture</b>	<b>Presentation</b>
11/21	Tel-Aviv University School of Public Health Seminar	Tel-Aviv	The role of nutrition in non- alcoholic fatty liver disease; evidence and reality
05/22	Spanish Precision Medicine forum	Zoom	A patient guideline (and the non- expert physician)
05/22	10th NAFLD Study Group Meeting 2022 (3rd virtual) Mitochondria, Biomarkers, and Treatment of NAFLD	Zoom	Lessons from recent dietary intervention trials
11/23	Meuhedet Healthcare multidisciplinary school for the treatment of children, adolescents, and adults with obesity.	Zoom	Obesity and liver disease

## 9. Research Grants

### a. Grants Awarded

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by</b> (V= "VATAT" - Council for Higher Education, C= other Competitive Funds)	<b>Amount NIS</b>	<b>Years</b>	<b>Publications</b>
Co-PI	Prof. Ran Oren Co-PI	Calcium intake and metabolic syndrome	Tnuva Research Fund. (C)	40,000	2002	D2, D5
Co-PI	Prof. Ran Oren Co-PI	The Prevalence of primary nonalcoholic fatty liver disease (NAFLD) in the Israeli population and the association with biochemical and anthropometric measures	Research fund of the Institute for the Research of the Influence of Food on Human Health and Quality of Life. (C)	20,000	2005	D2

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by</b> (V= "VATAT" - Council for Higher Education, C= other Competitive Funds)	<b>Amount NIS</b>	<b>Years</b>	<b>Publications</b>
Co-PI	Prof. Ran Oren Dr. Hanny Yeshua Co-PIs	The association between treatment with drugs inhibiting the renin-angiotensin (RAS) system and NAFLD in type-2 diabetic patients	Chief Scientist Office, Ministry of Health, feasibility study. (V)	25,000	2009	–
PI		Screening policy for cardiovascular disease in Israel: should non-HDL cholesterol be routinely included in risk assessment?	Pfizer research grant.	10,000	2010	–
PI	Prof. Tamar Shohat Collaborator	Trends in serum 25(OH)D distribution in the Israeli population in the last decade	Pfizer research grant.	10,000	2011	–
Co-PI	Dr. Richard J Schuster, Dr. Hanny Yeshua, Dr. Colleen O'Brien Cherry Co-PIs	Comparing Physician Cardiovascular Disease Risk Factor Management in Israel and the United States	Pfizer research grant.	37,000	2013	–
PI	Dr. Salman Zarka Collaborator	Estimation of liver disease burden in Israel by postmortem material for the establishment of a screening policy in children and adults	Pfizer research grant.	12,000	2013	–
Co-PI	Dr. Oren Shibolet Co-PI Dr. Eran Elinav Collaborator	A cross-sectional study intake, diet pattern and the microbiota profile among bariatric candidates	Fund on Food and Nutrition with Implications on Public Health. Chief Scientist Office, Ministry of Health. (V)	654,000	2014	D34, D45

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by</b> (V= "VATAT" - Council for Higher Education, C= other Competitive Funds)	<b>Amount NIS</b>	<b>Years</b>	<b>Publications</b>
PI	Dr. Samah Hayek Co-PI	Quality measures for community medicine from the patients' point of view on primary Care physician performance by ethnic and geographic region in Israel	The Israeli National institute for health policy research. (C)	148,940	2015	-
PI	#Dana Ivancovsky PhD Student	The association between the type of meat and cooking method, NAFLD and insulin resistance	Research Projects and Fellowships Fund on Food and Nutrition with Implications on Public Health. Chief Scientist Office, Ministry of Health. (V)	450,000	2016	D71
Collaborator	Dr. Ofir Ben-Assuli, Dr. Shani Shenhar-Tsarfaty PIs	Prediction of fatty liver and fibrosis by advanced data mining	National institute for health policy research. (C)	128,150	2019	-
PI	Prof. Oren Tirosh Co-Investigator	Novel Processed Food Compounds Leading to Metabolic Alterations and Liver Damage: Evaluation in mouse models and humans	Chief Scientist Office, Ministry of Health. (V)	400,000	2020	-
PI	Prof. Oren Tirosh Co-Investigator	The possible protective association of milk fat consumption with oxidative stress, pro-inflammatory metabolites and NAFLD	Chief Scientist Office, Ministry of Health. (V)	150,000	2021	-

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by (V= "VATAT" - Council for Higher Education, C= other Competitive Funds)</b>	<b>Amount NIS</b>	<b>Years</b>	<b>Publications</b>
Co-PI	Dr. Yftach Gepner Co-PI	The effects of time-restricted eating and exercise training on cardio-metabolic health, liver fat and body composition	ISF Personal Research Grants (V)	1,000,000	2022	-

**b. Submission of Research Proposals – Pending**

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funds Requested Agency</b>	<b>Amount NIS</b>	<b>Years</b>
Partner and WP leader	ISGLOBAL coordinator	SLINT: Steatotic Liver Impact Network and Training	HORIZON- MSCA-2023- DN-01-01	4198176 euro (542865.6 for university of Haifa)	5 years
PI	Co-investigator Yftach Gepner	The effect of ultra-processed food reduction on liver steatosis and fibrosis, cardiometabolic risk, and circulating bisphenol A in Metabolic dysfunction-associated steatotic liver disease (MASLD) patients	Ministry of Health - Chief Scientist Office	194,700	3 years

**c. Submission of Research Proposals – Not Funded**

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by (C= Competitive Fund)</b>	<b>Years</b>	<b>Score</b>
PI	-	Discriminatory metabolic, inflammatory and lifestyle parameters between the "metabolically healthy" and the "metabolically unhealthy" obese individuals	The Israel Science Foundation (ISF) \$311,000 (V)	2013	-

<b>Role in Research</b>	<b>Other Researchers (Name &amp; Role)</b>	<b>Title</b>	<b>Funded by (C= Competitive Fund)</b>	<b>Years</b>	<b>Score</b>
Researcher	Dr. Oren Shibolet Dr. Eran Elinav PIs	A step towards personalized drug treatment-elucidating the role of gut pharmacomicrobiomics in drug-induced liver injury	Weizmann Institute of Science – Tel Aviv Medical Center Collaborative Grant \$100,000	2013	-
Co-PI Head of two work packages		Liver molecular Mechanisms to Explain Progression of Insulin resistance into Emerging diseases and comorbidities (LIME-PIE)	Horizon 2020, European Commission. Understanding common mechanisms of diseases and their relevance in comorbidities. (C)	2015	-
Co-PI	Doron Kliger Mor Peleg Co-PIs	Mobile Behavioral-Economics (MoBEcon): a rule-based framework for pre-teens health behavior enhancement, employing behavioral economics incentives	Ministry of Science, Technology and Space (V)	2016	-
PI	Eran Segal Collaborator	Personalized nutrition by prediction of glycemic responses in women with gestational diabetes mellitus	The Israel Science Foundation (ISF) (V)	2016	-
PI	Eran Segal Collaborator	Personalized nutrition by prediction of glycemic responses in women with gestational diabetes mellitus	The Israel Science Foundation (ISF) (V)	2017	-
Co-PI	Revital Kariv Co- PI	The association between dairy consumption and colorectal polyps or cancer and NAFLD	Ministry of Health and the Israeli Dairy Board (C)	2017	-
Co-PI	Mor Peleg Co- PI	Devising a mobile behavioral-economics knowledge-based (MoBEcon) framework for supporting compliance to health goals: prototype development and experimental evaluation	The Israel Science Foundation (ISF) (V)	2018	-

Role in Research	Other Researchers (Name & Role)	Title	Funded by (C= Competitive Fund)	Years	Score
PI	Profs: Tirosh Oren, Ronit Shiri-Sverdlov, Jörn Schattenberg, Manuel Romero-Gómez Collaborators	Novel Processed Food Compounds Leading to Obesity-Related Metabolic Alterations and Liver Damage	JPI-HDHL-INTIMIC Call for Joint Transnational Research Proposals: "Impact of Diet, Food Components Processing on Body Weight Regulation and Overweight Related Metabolic Diseases (METADIS)" (C)	2019	-
Collaborator	Manuel Romero-Gómez PI	Combinatorial Therapies in Complex Metabolic Disorders: integrating non-alcoholic fatty liver disease (COMET-NAFLD)	H2020-SC1-BHC-2018-2020 (C)	2019	11.5 (Out Of 12)
Co-PI	Prof. Revital Kariv Co-PI	The association between ultra-processed food consumption, microbiome diversity and colonic neoplastic outcomes	Israel Cancer Association Research Grant (C)	2019	-
Co-PI	Dr. Yftach Gepner Prof. Uri Gophna Co-PIs	Personalized exercise and dietary modifications for liver steatosis and fibrosis remission; from randomized clinical trial to clinical application	ISF Personalized medicine (V)	2021	-

#### 10. Scholarships, Awards and Prizes

2002	Received a prize for excellent doctoral students from the Wolf Foundation.
2007	Young Investigator Award, The European Association for the Study of the Liver.
2020	Leading publisher (with highest impact factor scientific publications) in the Faculty of Social Welfare and Health Sciences, University of Haifa

11. **Teaching**

a. **Courses Taught in Recent Years**

<b>Year</b>	<b>Name of Course</b>	<b>Type of Course Lecture/Seminar/ Workshop/ Online Course/ Introduction Course (Mandatory)</b>	<b>Level</b>	<b>Number of Students</b>
<b>2006-2011</b>	Nutrition in liver diseases	Workshop	B.A	80
<b>2008- 2013</b>	Meta analysis	Lectures	M.A./ Master in Applied Nutrition (MAN)/Ph.D.	8
<b>2009-present</b>	Making sense of data	Lectures	M.A./MAN/Ph.D.	20
<b>2009-present</b>	Nutritional Epidemiology	Lectures	M.A./MAN/Ph.D.	23
<b>2009-present</b>	Construction of a research proposal	Lectures	M.A./MAN/Ph.D.	30
<b>2010-present</b>	Epidemiology of cardiovascular disease	Lectures	M.A./MAN/Ph.D.	10
<b>2010- 2014</b>	Applied research	Lectures	M.A./MAN/Ph.D.	8
<b>2013- 2019</b>	Epidemiology	Lectures	B.A. Pre-medical	44
<b>2014-present</b>	Advanced clinical nutrition	Lectures	MAN/Ph.D.	12
<b>2016</b>	Advanced epidemiology	Lectures	M.A./MAN/Ph.D.	15
<b>2018</b>	Research methods	Lectures	M.A./MAN/Ph.D.	90
<b>2018</b>	Scientific writing	Lectures	M.A./MAN	40
<b>2020</b>	Doctoral Forum	Lectures and student presentations	Ph.D.	25

b. **Supervision of Graduate Students**

<b>Name of Student</b>	<b>Name of Other Mentors</b>	<b>Title of Thesis</b>	<b>Degree</b>	<b>Year of Completion/ In Progress</b>	<b>Student's Achievements</b>
Isaak Winocur Michal	Prof. Oren Ran	Hepato-renal index (HRI) and anthropometric and biochemical measures among patients of the fatty liver clinic	MD research adviser	2011	- (score 90)

Name of Student	Name of Other Mentors	Title of Thesis	Degree	Year of Completion/ In Progress	Student's Achievements
Lotan Roni Co-supervisor	Prof. Oren Ran	Incidence of non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome components, a follow-up study	MPH	2012	See D14, D20, D22, D25, D36 (score 89)
Buch Assaf	Prof. Shibolet Oren	Physical activity as a treatment for NAFLD	MPH	2013	See D23 (score 93)
Ben Abu Maya	Dr. Prof. Dubno Raz Gal	Factors associated with adherence to weight reduction and physical activity program in obese children	Master in Applied Nutrition (MAN)	2013	- (score 88)
Awawdi Khaled†	Prof. Green Manfred	Exposure to passive smoking among Arab women with acute MI as compared to controls	MPH	2013	See D31 (score 94)
Yair-Sabag Shira		The association between viral hepatitis and metabolic syndrome	MPH	2013	See D43 (score 92)
Harari Gil	Prof. Green Manfred	Physical activity at work and at leisure time and all-cause and cardiovascular mortality	MPH	2013	See D29 (score 93)
Abed Petra		Non-HDL cholesterol and cardiovascular mortality	MAN	2014	- (score 91)
Dror-Lavi Gali		Knowledge attitudes and practices of NAFLD patients concerning lifestyle modification as compared to diabetic patients	MAN	2014	See D49 (score 87)
Solomon Esti		Nutrition Pattern and NAFLD	MAN	2014	- (score 92)
Schlesinger Dalit		The association between NAFLD and quality of life (QOL) parameters and utilization of health services in Israeli Jewish population	MAN	2014	See D36 (score 94)
Goldshmidt Moyal Reut	Dr. Kariv Revital	The association between state and trait anxieties, dietary patterns and NAFLD	MAN	2014	- (score 92)
Damari Moria	Prof. Chowers Yehuda	Anxiety from eating and eating patterns among inflammatory bowel disease patients	MAN	2016	- (score 91)
Shoham	Dr. Sigal	Disordered eating (night and	MAN	2016	See D46



Name of Student	Name of Other Mentors	Title of Thesis	Degree	Year of Completion/ In Progress	Student's Achievements
Dafna	Fishman	binge eating) among morbid obese patients and the association with hepatic fibrosis			(score 91)
Ivancovsky Dana	Dr. Kariv Revital	The association between the type of meat and cooking method, and NAFLD	MAN	2016	See D71 (score 95)
Margalit Dana	Dr. Kariv Revital	The association between the type of meat and cooking method, and colorectal polyps	MAN	2017	See D72, D92 (score 92)
Zur Reut	Dr. Kariv Revital	The association between serum 25-OH Vitamin D and NAFLD	MAN	2017	See D86 (score 91)
Pirian Daniella	Dr. Levin-Zamir Diane	The effect of tailored short message service (SMS) on compliance to treatment and glycemic control among type-2 diabetes patients	MAN	2018	- (score 88)
Tal Naama	Dr. Mishali Moshe	The association between social resistance to milk and dairy products consumption and: health perception and behavior, locus of control and hypochondria	MAN	2018	- (score 83)
Brand Ronen	Prof. Karkabi Khaled	Barriers to adherence with oral anti-hyperglycemic medications and their correlation with adherence rate: a cross-sectional study in three sub-populations in Israel	MPH	2018	- (score 92)
Tal Tamar	Dr. Nachmani Sharon	Disorder eating and food addiction among bariatric patients	MAN	2017	(score 90)
Shai Shiran	Prof. Shibolet Oren	Comparison between NAFLD, cirrhosis, and liver transplant patients in space living, frailty and quality of life parameters	MAN	2019	(score 91)
Sabargili Chen	Maharshak Nitzan	Validation of processed food frequency questionnaire in inflammatory bowel disease patients	MPH	2019	See D101 (score 90)
Frish Keren	Dr. Kariv	The association of sleep	MAN	2020	(score 89)

Name of Student	Name of Other Mentors	Title of Thesis	Degree	Year of Completion/ In Progress	Student's Achievements
	Revital	quality and eating patterns with NAFLD			
Seri Noa	Dr. Sigal Fishman	Irritable bowel disease among bariatric surgery patients	MAN	2020	(score 89)
Frij Alaa	Prof. Dubnov-Raz Gal	Daily energy requirements of Severe Combined Immunodeficiency patients	MAN	2020	(score 87)
Shamshoum Najwan	Dr. Ravi Hazan	Meat intake and liver fibrosis NAFLD patients	MAN	2020	(score 89)
Koifman Chen	Prof. Kariv Revital	The association between body composition/hand grip strength with colonic polyps among population with average risk for colorectal cancer	MAN	2022	(score 94)
Yamin Moria	Prof. Kariv Revital	The association between body composition/hand grip strength with NAFLD	MAN	2022	(score 95)
Berman Hila		The association of poor sleep quality and abnormal sleep duration with non-alcoholic fatty liver disease	MPH	2022	(score 95)
Sencelsky Yael		Predictors of weight loss success in overweight pre-diabetic adults in mobile based interventions, examined via Lumen device pilot study	MAN	in Progress	(score 89)
Paz Dubinsky Efrat	Dr. Anbar Ronit	The impact of a vegan diet on pregnancy outcomes	MAN	2022	(score 94)
Rot Yaara		NAFLD and eating behavior habits	MAN	in Progress	-
Sheinman Einav		Physical activity and NAFLD, a prospective study	MAN	in Progress	-
Margol Dina		Quality evaluation of health system by medical mistakes and its consequences	MHA	2023	(score 89)
Hardon Hadas		The association between multiple sclerosis and the metabolic syndrome	MAN	2023	(score 91)
Berko Zohar		The effect of nutritional treatment on chronic kidney	MAN	in Progress	-

Name of Student	Name of Other Mentors	Title of Thesis	Degree	Year of Completion/ In Progress	Student's Achievements
		disease progression among patients with type-2 diabetes			
<b>Ph.D. Students</b>					
Fliss Naomi	Dr. Kariv Revital	The association between adenomas and metabolic syndrome and NAFLD	Ph.D	2017	See D54, D65, D71, D72, D76, D78,
Sherf Shiri	Prof. Shibolet Oren	Probiotics vs. placebo as a treatment for NAFLD patients, randomized double-blind clinical trial	Ph.D	2017	See D34, D44, D56, D62, D80, D83
Harari Gil	Prof. Green Manfred	Development of a Risk Prediction Model for Cardiovascular Mortality in the CORDIS Cohort	Ph.D	2017	See D48, D57
Rasha Daniel	Prof. Zuckerman Eli	The epidemiology of hepatitis E virus infection in Israel and potential risk factors	Ph.D	2022	-
Halaf Kridin	Dr. Cohen Arnon	Epidemiology of Pemphigus Vulgaris and its association with metabolic syndrome and autoimmune comorbidities in an Israeli population	Ph.D	2018	See D37, D42, D52, D53, D55, D59, D64, D67, D68, D69, D70, D77, D79, D82, D106
Ivancovsky Dana	Prof. Kariv Revital	Nutritional profile as a basis For long-term prospective metabolic and neoplastic outcomes	Ph.D	2022	See D72, D87, D89, D92, D93, D95, D102, D105, D110, D116 Awarded a prize of excellence in research (oral presentation) at the United European Gastroenterology (UEG) Conference 2018
Michal Rein	Prof. Eran Segal	A randomized clinical trial on the effect of personalized nutrition, based on personal glycemic response, on glycemic control and pregnancy outcomes among women with gestational diabetes	Ph.D	in Progress	See D133

<b>Name of Student</b>	<b>Name of Other Mentors</b>	<b>Title of Thesis</b>	<b>Degree</b>	<b>Year of Completion/ In Progress</b>	<b>Student's Achievements</b>
Zur Reut	Prof. Kariv Revital	The association between eating patterns, changes in eating habits over time and lifestyle-related measures with gastrointestinal polyps among average and high-risk populations	Ph.D	in Progress	-
Zittan Eran	Prof. Mark S. Silverberg	Development and Validation of a New Endoscopy Score for Inflammatory Bowel Disease (IBD), The TIGER score	Ph.D	in Progress	See D118
Laura Grinshpon	Prof. Kariv Revital	The association of ultra-processed food (UPF) consumption with non-alcoholic fatty liver disease (NAFLD), and the role of gut microbiome and genetic predisposition	Ph.D Direct	in Progress	-
Sabargili Chen	Maharshak Nitzan	Processed food and inflammatory bowel disease	Ph.D	in Progress	-

## **PUBLICATIONS**

<b>H-index:</b>	37 (46)	<b>Source:</b> ISI (Google Scholar)
<b>Citation index:</b>	6,673 (without self-citations)	<b>Source:</b> ISI
<b>ORCID number:</b>	0000-0002-1324-7497	
<b>Google Scholar link:</b>	<a href="https://scholar.google.com/citations?user=K4rJUT8AAAAJ">https://scholar.google.com/citations?user=K4rJUT8AAAAJ</a>	

**Note:** In accordance with accepted procedure for medical and science authorship order, first or last placement of name indicates that author played the major role in the reported study, unless mentioned otherwise.

### **A. Ph.D. Dissertation**

**Title:** The prevalence of primary nonalcoholic fatty liver disease (NAFLD) in Israeli population, and the association with biochemical, anthropometric and nutritional measures.

**Date of submission:** May 2007

**Number of pages:** 168

**Language:** English

**University:** Sackler School of Medicine, Tel Aviv University.

#### **Names of supervisors (Ph.D.):**

Prof Ran Oren, M.D. Sackler School of Medicine, Tel Aviv University.

Prof Zamir Halpern, M.D. Sackler School of Medicine, Tel Aviv University.

Dorit Nizan Kaluski, M.D., MPH, R.D. Sackler School of Medicine, Tel Aviv University.

**See publications list:** D2, D4, D5, D8.

### **B. Scientific Books (Refereed)**

None

### C. Monographs

None

### D. Articles in Refereed Journals

#### Published

*	Publications since last appointment
#	My student
+	Corresponding author
IF = Impact factor	Obtained from ISI at the year of publication
R = Ranking	Obtained from ISI at the year of publication
Q = Quartile	Obtained from ISI at the year of publication
V = Vatat List	Vatat List (The Council for Higher Education)

1. **+Zelber-Sagi, S.**, Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M., Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2006). A double-blind randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*. (4) 639-44.  
(IF 7.680, Rank=7/79 in, Gastroenterology& Hepatology Q1, V)
2. **+Zelber-Sagi, S.**, Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2006). Prevalence of primary NAFLD in a population-based study and its association with biochemical and anthropometric measures. *Liver International*. (26) 856-63.  
(IF 2.344, Rank=21/48 in, Gastroenterology& Hepatology Q2, V)
3. Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., Noff, D., **Zelber-Sagi, S.**, Sheinberg, B. Oren, R., Halpern, Z. (2006). Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. *Liver International*. (26) 445-50.  
(IF 2.344, Rank=21/48 in, Gastroenterology& Hepatology Q2, V)
4. **+Zelber-Sagi, S.**, Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2007). NAFLD and serum insulin are major determinants of serum ferritin levels. *Journal of Hepatology*. (46) 700-7.  
(IF 6.642, Rank=4/50 in, Gastroenterology& Hepatology Q1, V)  
Related editorial:  
Trombini, P., Piperno, A. Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons. (2007) *Journal of Hepatology*. (46) 549-52.
5. **+Zelber-Sagi, S.**, Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., Oren, R. (2007). Long-term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. *Journal of Hepatology*. (47) 711-7.  
(IF 6.642, Rank=4/50 in, Gastroenterology& Hepatology Q1, V)

6. Lurie, Y., Landau, DA., Kanevsky, A., Pel, S., **Zelber-Sagi, S.**, Oren, R. (2007). Medex test, a novel modality for liver disease diagnosis: a pilot study. *Journal of Clinical Gastroenterology*. (41) 700-5.  
(IF 2.938, Rank=18/50 in, Gastroenterology& Hepatology Q2, V)
  
7. Lurie, Y., Landau, DA., Blendis, L., Baruch, Y., Veitsman, E., Ackermann, Z., **Zelber-Sagi, S.**, Halpern, Z., Oren, R. (2007). Acute hepatitis C in Israel: a predominantly iatrogenic disease? *Journal of Gastroenterology and Hepatology*. (22) 158-64.  
(IF 1.673, Rank=38/50 in, Gastroenterology& Hepatology Q4, V)
  
8. **+Zelber-Sagi, S.**, Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., Oren, R. (2008). Role of leisure-time physical activity in non-alcoholic fatty liver disease (NAFLD): A population based study. *Hepatology*. (48) 1791-8.  
(IF 11.355, Rank=2/55 in, Gastroenterology& Hepatology Q1, V)
  
9. +Webb, M., Yeshua, H., **Zelber-Sagi, S.**, Santo, M., Brazowski, E., Halpern, Z., Oren, R. (2009). The Diagnostic Value of a Computerized Hepatorenal Index for Ultrasonographic Quantification of Liver Steatosis. *American Journal of Roentgenology*. (192) 909-14.  
(IF 2.951, Rank=21/104 in, Radiology, Nuclear Medicine & Medical Imaging Q2, V)
  
10. Ratziu, V., **Zelber-Sagi, S.** (2009). Pharmacologic therapy of non-alcoholic steatohepatitis. Review. *Clinics in Liver Disease*. (13) 667-88.  
(IF 2.944, Rank=31/79 in, Gastroenterology& Hepatology Q2, V)
  
11. **+Zelber-Sagi, S.**, Ratziu, V., Oren, R. (2011). Nutrition and physical activity in NAFLD – an overview of the epidemiological evidence. Review. *World Journal of Gastroenterology*. (17) 3377-89.  
(IF 2.471, Rank=32/74 in, Gastroenterology& Hepatology Q2, V)  
Related "Topic highlight":  
Nimer, A. (2011). Nutritional recommendations for patients with non-alcoholic fatty liver disease. *World Journal of Gastroenterology*. (17) 3375–6.
  
12. **+Zelber-Sagi, S.**, Yeshua, H., Shlomain, A., Blendis, L., Leshno, M., Levit, S., Halpern, Z., Oren, R. (2011). Sampling variability of transient elastography according to probe location. *European Journal of Gastroenterology & Hepatology*. (23) 507-14.  
(IF 1.757, Rank=51/74 in, Gastroenterology & Hepatology Q3, V)
  
13. Maharshak, N., Halfon, P., Deutsch, V., Peretz, H., Berliner, S., Fishman, S., **Zelber-Sagi, S.**, Rozovski, U., Leshno, M., Oren, R. (2011). Increased fibrosis progression rates in hepatitis C patients who carry the PTG20210A mutation. *World Journal of Gastroenterology*. (17) 5007-13.  
(IF 2.471, Rank=32/74 in, Gastroenterology& Hepatology Q2, V)
  
14. **+Zelber-Sagi, S.**, #Lotan, R., Shlomain, A., Webb, M., Harrari, G., Buch, A., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2012). Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *Journal of Hepatology*. (56) 1145-51.  
(The first and the second authors contributed equally to the paper).

(IF 9.858, Rank=5/74 in, Gastroenterology& Hepatology Q1, V)

15. +**Zelber-Sagi, S.**, Ratziu, V., Zvibel, I., Goldiner, I., Blendis, L., Morali, G., Halpern, Z., Oren, R (2012). The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. *European Journal of Gastroenterology & Hepatology*. (24) 262-9.  
(IF 1.915, Rank=48/74 in, *Gastroenterology & Hepatology* Q3, V)
16. Salamone, F., Volti, GL., Titta, L., Barbagallo, I., Puzzo, L., **Zelber-Sagi, S.**, Pelicci, PG., Giorgio, M., Galvano, F. (2012). Moro orange juice prevents fatty liver in mice. *World Journal of Gastroenterology*. (18) 3862-8.  
(IF 2.547, Rank=34/74 in, Gastroenterology& Hepatology Q2, V)
17. Shlomai, A., Halfon, P., Goldiner, I., **Zelber-Sagi, S.**, Halpern, Z., Oren, R., Bruck, R. (2013). Serum Bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. *Journal of Viral Hepatitis*. (20) 95-102.  
(IF 3.307, Rank=22/75 in, Gastroenterology& Hepatology Q2, V; Rank= 21/72 in, Infectious Diseases Q2, V)
18. +**Zelber-Sagi, S.**, Webb, M., Assy, N., Blendis, L., Yeshua, H., Leshno, M., Ratziu, V., Halpern, Z., Oren, R., Santo, E. (2013). Comparison of fatty liver-index with non-invasive methods for steatosis detection and quantification. *World Journal of Gastroenterology*. (19) 57-64.  
(IF 2.433, Rank=36/75 in, Gastroenterology& Hepatology Q2, V)
19. +**Zelber-Sagi, S.**, Toker, S., Armon, G., Melamed, S., Berliner, S., Shapira, I., Halpern, Z., Santo, E., Shibolet O. (2013). Elevated alanine transaminase independently predicts new onset of depression in employees undergoing health screening examinations. *Psychological Medicine*. (22) 1-11.  
(The first and the second authors contributed equally to the paper).  
(IF 5.428, Rank=8/74 in, Psychology Q1, V) (Rank = 16/136 in, Psychiatry (SCIE) Q1,V)
20. +**Zelber-Sagi, S.**, #Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan-Kaluski, D., Halpern, Z., Santo, E., Oren, R. (2013). NAFLD independently predicts type-2 diabetes and pre-diabetes during a seven-year prospective follow-up. *Liver international*. 33(9):1406-12.  
(IF 4.447, Rank=14/75 in, Gastroenterology& Hepatology Q1, V)
21. +Endevelt, R., Ben-Assuli, O., Klain, E., **Zelber Sagi, S.** (2013). The role of the dietitian follow-up in the success of bariatric surgery. *Surgery for Obesity and Related Diseases*. 9(6):963-8.  
(IF 4.942, Rank=7/204 in, Surgery Q1, V)
22. +**Zelber-Sagi, S.**, Salamone, F., Yeshua, H., #Lotan, R., Webb, M., Halpern, Z., Santo, E., Oren, R., Shibolet, O. (2014). Non-high density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. *Liver international*. 34(6) e128-35.  
(IF 4.850, Rank=13/76 in, Gastroenterology& Hepatology Q1, V)



23. **+Zelber-Sagi S.**, #Buch A., Yeshua H., Vaisman N., Webb M., Harari G., Kis O., Fliss-Isakov N., Izkhakov E., Halpern Z., Santo E., Oren R., Shibolet O. (2014). Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. *World Journal of Gastroenterology*. 20(15) 4382-92.  
(IF 2.369, Rank=41/76 in, Gastroenterology& Hepatology Q3, V)
24. Safadi, R., Konikoff, F.M., Mahamid, M., **Zelber-Sagi, S.**, Halpern, M., Gilat, T., Oren R; FLORA group. (2014). The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*. 12(12) 2085-91.  
(IF 7.896, Rank=7/76 in, Gastroenterology& Hepatology Q1, V)
25. **+Zelber-Sagi, S.**, Salomone, F., Webb, M., #Lotan, R., Yeshua, H., Halpern, Z., Santo, E., Oren, R., Shibolet, O. (2014). Coffee consumption and non-alcoholic fatty liver onset: a prospective study in the general population. *Translational Research*. 165(3):428-36.  
(IF 5.030, Rank=2/30 in, Medical Laboratory Technology Q1, V; Rank=17/154 in, Medicine, General & Internal Q1, V; 17/123 in, Medicine, Research & Experimental Q1, V)
26. Schuster, RJ., Cherry, CO., **Zelbar-Sagi, S.**, Yeshua, H., Matalon, A., Steichen, O., Duhot, D., Fujiyoshi, A., and Miura, k. (2014) .Cross-Cultural Analysis of Physician Management of Obesity. Comparing the US, France, Israel and Japan: Little Interest and Little Success. *Primary Health Care*. 4:3 (5 pages). IF: none
27. Khatib, M., Zvibel, I., **Zelber-Sagi, S.**, Varol, C., Lahat, G., Abu-Abeid, S., Klausner, J. M., Halpern, Z., Fishman, S. (2014). Discriminatory metabolic and inflammatory parameters in serum and omental adipose tissue of obese patients with different insulin sensitivity. *Journal of Clinical & Translational Endocrinology*. 1(3):115–119. The first two authors contributed equally to the article.  
IF: none  
(SJR 2015=0.398, Rank=133/211 in, Endocrinology, Diabetes & Metabolism Q3)
28. Grossman, A., Ben Assouli, O., **Zelber-Sagi, S.**, Golbert, R., Matalon, A., & Yeshua, H. (2015). The management of pre-hypertension in primary care-Is it adequate? *Blood pressure*. 24(4):237-41.  
(IF 2.010, Rank=42/63 in, Peripheral Vascular Disease Q3, V)
29. #Harari, G., Green, SM., **Zelber-Sagi, S.** (2015). Combined association of occupational and leisure-time physical activity with all-cause and coronary heart disease mortality among a cohort of men followed-up for 22 years. *Occupational and Environmental Medicine*. 72(9): 617-24.  
(IF 3.745, Rank=22/173 in, Public, Environmental & Occupational Health Q1, V)
30. **+Zelber-Sagi, S.**, Ben-Assuli, O., Rabinowich, L., Goldstein, A., Magid, A., Shalev, V., Shibolet, O., Chodick, G. (2015). The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. *Liver International*. 35(11): 2408-15.  
(IF 4.470, Rank=13/79 in, Gastroenterology& Hepatology Q1, V)

31. #Awawdi, K., Steiner, H., Green, MS., **Zelber-Sagi, S.** (2015). Association between second-hand smoking and acute coronary heart disease among Arab women with multiple risk factors. *European Journal of Public Health*. 26(1):141-5.  
(IF: 2.751, Rank=18/153 in, Public, Environmental & Occupational Health Q1, V)
  
32. Salomone, F., Godos, J., **Zelber-Sagi, S.** (2015). Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. *Liver International*. 36(1):5-20.  
(IF 4.470, Rank=13/79 in, Gastroenterology& Hepatology Q1, V)
  
33. Salomone, F., **Zelber-Sagi, S.**, Galvano, F., Fabbrini, E. (2015). Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management. *BioMed Research International*. Editorial. 2015:153276. (1 page).  
(IF 2.134, Rank=72/124 in, Medicine, Research & Experimental Q3, V)
  
34. #Dagan Sherf, S., **Zelber-Sagi S.**, Webb, M., Keidar, A., Raziell, A., Sakran, N., Goitein, D., Shibolet, O. (2016). Nutritional Status Prior to Laparoscopic Sleeve Gastrectomy Surgery. *Obesity Surgery*. 26(9):2119-26.  
(IF 3.346, Rank=23/200 in, Surgery Q1, V)
  
35. Zaslavsky, O., Rillamas-Sun, E., LaCroix, AZ., Woods, NF., Tinker, LF., Zisberg, A., Shadmi, E., Cochrane, B., Edward, BJ., Kritchevsky, S., Stefanick, ML., Vitolins, MZ., Wactawski-Wende, J., **Zelber-Sagi, S.** (2016). Association between anthropometric measures and long-term survival in frail older women: Observations from the women's health initiative study. *Journal of the American Geriatrics Society*. 64(2):277-84.  
(IF 3.842, Rank=8/49 in, Geriatrics & Gerontology Q1, V; Rank= 2/32 in, Gerontology Q1, V)
  
36. Mlynarsky, L., #Schlesinger, D., #Lotan R., Webb, M., Halpern, Z., Santo, E., Shibolet, O., **Zelber-Sagi, S.** (2016). Non-alcoholic fatty liver disease is not associated with a lower health perception. *World Journal Gastroenterology*. 22(17):4362-72.  
(IF 2.787, Rank=38/79 in, Gastroenterology& Hepatology Q2, V)
  
37. #Kridin, K., Bergman, R., Khamaisi, M., **Zelber-Sagi, S.**, Weltfriend, S. (2016). Dermatitis Cement-Induced Chromate Occupational Allergic Contact. *Dermatitis*. 27(4):208-14. (IF 2.287, Rank=18/61 in Dermatology, Q2, V)
  
38. **+Zelber-Sagi, S.**, Godos, J., Salomone, F. (2016) Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. *Therapeutic Advances in Gastroenterology*.9(3):392-407.  
(IF 3.883, Rank=21/79 in, Gastroenterology& Hepatology Q2, V)
  
39. Zaslavsky, O., Woods, NF., LaCroix AZ., Cauley, JA., Johnson, KC., Cochrane, BB., **Zelber Sagi, S.** (2016). Identification of risk factors for mortality and low-quality-of-life survival in frail older women participating in Women's Health Initiative observational study. *Journal of the American Geriatrics Society*. 64:831–837.  
(IF 3.842, Rank=8/49 in, Geriatrics & Gerontology Q1, V; Rank= 2/32 in, Gerontology Q1, V)

40. Zaslavsky, O., **Zelber-Sagi, S.**, Shelly, L., Pharm, G., LaCroix, AZ., Brunner, RL., Wallace, RB., O'Sullivan, MJ., Cochrane, B., Woods, NF. (2016). Comparison of frailty phenotypes for prediction of mortality, incident falls, and hip fractures in older women. *Journal of the American Geriatrics Society*. 64(9):1858-62. (IF 3.842, Rank=8/49 in, Geriatrics & Gerontology Q1, V; Rank= 2/32 in, Gerontology Q1, V)
41. **+Zelber-Sagi, S.**, Azar, S., Nemirovski, A., Webb, M., Halpern, Z., Shibolet, O., Tam, J. (2016). Serum levels of endocannabinoids are independently associated with non-alcoholic fatty liver disease. *Obesity*. 25(1):94-101. (IF 3.614, Rank=18/80 in, Nutrition & Dietetics Q1, V)
42. #Kridin, K., **Zelber-Sagi, S.**, Khamaisi, M., Cohen, AD., Bergman, R. (2016). Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. *Journal of the American Academy of Dermatology*. 75(5):925-930. (IF 6.898, Rank=2/64 in, Dermatology Q1, V)
43. #Yair-Sabag, S., Nussinson, E., Ben-Assuli, O., Shibli, F., Shahbari, A., **Zelber-Sagi, S.** (2016). Retrospective study of the associations between hepatitis C virus infection and metabolic factors. *World J Hepatology*. 8(30):1269-1278.  
IF: none  
(SJR 2015= 0.858, Rank=21/54 in, Hepatology Q2)
44. #Sherf-Dagan, S., Ben-Tovim, T., Buch, A., Webb, M., Keidar, A., Raziell, A., Sakran, N., Goitein, D., Shibolet, O., **Zelber-Sagi, S.** (2017). Inadequate protein intake after laparoscopic sleeve gastrectomy surgery is associated with a greater fat free mass loss. *Surgery for Obesity and Related Diseases*. 13(1):101-109. (IF 3.540, Rank=17/200 in, surgery Q1, V)
- Related editorial: Gletsu-Miller N. (2017). Paired editorial: Inadequate protein intake following laparoscopic sleeve gastrectomy surgery is associated with a greater fat free mass loss. *Surgery for Obesity and Related Diseases*.
45. Zaslavsky, O., Rillamas-Sun, E., Li, W., Going, S., Datta, M., Snetselaar, L., **Zelber-Sagi, S.** (2017). Association of dynamics in lean and fat mass measures with mortality in frail older women. *Journal of Nutrition, Health and Aging*. 21(1):112-119. (IF 3.199, Rank=14/49 in, Geriatrics & Gerontology Q2, V; Rank=29/80 in, Nutrition & Dietetics Q2, V)
46. **+Zelber-Sagi, S.**, #Shoham, D., Zvibel, I., Abu-Abeid, S., Shibolet, O., Fishman, S. (2017). Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. *World Journal of Hepatology*. 9(2):91-98.  
IF: none  
(SJR 2015= 0.858, Rank=21/54 in, Hepatology Q2)
47. **Zelber-Sagi, S.**, Salomone, F., Kolodkin, I., Erez, N., Buch, A., Yeshua, H., Webb, M., Halpern Z., Shibolet O. (2017). Protective role of soluble receptor for

- advanced glycation end-products in patients with non-alcoholic fatty liver disease. *Digestive and Liver Disease*. 49(5):523-529.  
(IF 2.719, Rank=40/79 in, Gastroenterology& Hepatology Q3, V)
48. #Harari, G., Green, MS., Magid, A., **Zelber-Sagi, S.** (2017). Usefulness of non-high density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22 Years. *American Journal of Cardiology*. 119(8):1193-1198.  
(IF 3.154, Rank=43/124 in, Cardiac & Cardiovascular Systems Q2, V)
49. **Zelber-Sagi, S.**, Bord, S., #Dror-Lavi, G., Smith, ML., Towne, SD., Buch A., Webb, M., Yeshua, H., Nimer A., Shibolet, O. (2017). Role of illness perception and self-efficacy in lifestyle modification among NAFLD patients. *World Journal of Gastroenterology*. 23(10):1881-1890.  
(IF 2.787, Rank=38/79 in, Gastroenterology& Hepatology Q2, V)
50. Zaslavsky, O., **Zelber-Sagi, S.**, Hebert, JR., Steck, SE., Shivappa, N., Tabung, FK., Wirth, MD., Bu, Y., Shikany, JM., Orchard, T., Wallace, RB., Snetselaar, L., Tinker, LF. (2017). Biomarker-calibrated nutrient intake and healthy diet index associations with mortality risks among older and frail women from the Women's Health Initiative. *American Journal of Clinical Nutrition*. 105(6):1399-1407.  
(IF 6.703, Rank=3/80 in, Nutrition & Dietetics Q1, V)
51. **Zelber-Sagi, S.**, Salomone, F., Mlynarsky, L. (2017). The Mediterranean dietary pattern as the diet of choice for NAFLD; evidence and plausible mechanisms. *Liver International*. 7(7):936-949. **Invited review**.  
(IF 4.470, Rank=13/79 in, Gastroenterology& Hepatology Q1, V)
52. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, AD. (2017). Ulcerative colitis associated with pemphigus: a population-based large-scale study. *Scandinavian Journal of Gastroenterology*. 52(12):1360-1364.  
(IF 2.526, Rank=50/79 in, Gastroenterology& Hepatology Q3, V)
53. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, AD. (2017). Association between pemphigus and psoriasis: A population-based large-scale study. *Journal of the American Academy of Dermatology*. 77(6):1174-1175.  
(IF 7.002, Rank=1/63 in, Dermatology Q1, V )
54. #Fliss-Isakov, N., **Zelber-Sagi, S.**, Webb, M., Halpern, Z., Kariv, R. (2017). Distinct metabolic profiles are associated with colorectal adenomas and serrated polyps. *Obesity*. Suppl 2:S72-S80.  
(IF 3.873, Rank=18/81 in, Nutrition & Dietetics Q1, V)  
**(The first and the second authors contributed equally to the paper).**
55. #Kridin K., **Zelber-Sagi S.**, Comaneshter D., Cohen AD. (2017). Is there an association between pemphigus and hepatitis viruses? A population-based large-scale study. *Immunologic Research*. 65(5):1083-1088.  
(IF 2.905, Rank=82/151 in, Immunology Q3, V)
56. #Sherf Dagan, S., **Zelber-Sagi, S.**, Zilberman-Schapira, G., Webb, M., Buch, A., Keidar, A., Raziell, A., Sakran, N., Goitein, D., Goldenberg, N., Ali Mahdi, J., Pevsner-Fischer,

M., Zmora, N., Dori-Bachash, M., Segal, E., Elinav, E., Shibolet, O. (2018). Probiotics administration following Sleeve Gastrectomy surgery: a randomized double-blind trial. *International Journal of Obesity*. 42(2):147-155.  
(IF 5.337, Rank=6/80, in Nutrition & Dietetics Q1, Rank=18/133 in, Endocrinology & Metabolism Q1, V)

**(The first and the second authors contributed equally to the paper).**

57. #Harari, G., Green, MS., **Zelber-Sagi, S.** (2017). Estimation and development of 10- and 20-year cardiovascular mortality risk models in an industrial male workers database. *Preventive Medicine*. 103:26-32.

(IF 2.893, Rank=34/173 in, Public, Environmental & Occupational Health Q1, Rank=25/155 in, Medicine, General & Internal Q1, V)

58. Romero-Gómez, M., **Zelber-Sagi, S.**, Trenell, M. (2017). Treatment of NAFLD with diet, physical activity and exercise. *Journal of Hepatology*. 67(4):829-846. **Invited review.**

(IF 10.590, Rank=5/79 in, Gastroenterology & Hepatology Q1, V)

**(The three authors contributed equally to the paper).**

59. #Kridin, K., **Zelber-Sagi, S.**, Bergman R. (2017). Pemphigus Vulgaris and Pemphigus Foliaceus: differences in epidemiology and mortality. *Acta Dermato-Venereologica*. 97(9):1095-1099.

(IF 3.653, Rank=8/63 in, Dermatology Q1, V)

60. Zaslavsky, O., **Zelber-Sagi, S.**, LaCroix, AZ., Brunner, RL., Wallace, RB., Cochrane, BB., Woods NF. (2017). Comparison of the simplified sWHI and the standard CHS frailty phenotypes for prediction of mortality, incident falls, and hip fractures in older women. *The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences*. 72(10):1394-1400.

(IF 5.957, Rank=3/49 in, Geriatrics & Gerontology Q1, V)

61. Zaslavsky, O., Li W., Going, S., Datta, M., Snetselaar, L., **Zelber-Sagi S.** (2017). Association between body composition and hip fractures in older women with physical frailty. *Geriatrics & Gerontology International*. 17(6):898-904.

(IF 2.229, Rank=26/49 in, Geriatrics & Gerontology Q3, V)

62. #Sherf-Dagan, S., Keidar, A., Raziell, A., Sakran, N., Goitein, D., Shibolet, O., **Zelber-Sagi, S.** (2017). Do Bariatric Patients Follow Dietary and Lifestyle Recommendations during the First Postoperative Year? *Obesity Surgery*. 27(9):2258-2271.

(IF 3.346, Rank=23/200 in, Surgery Q1, V)

63. Weinstein, G., **Zelber-Sagi, S.**, Preis, SR., Beiser, AS., Decarli, C., Speliotes, EK., Satizabal, C., Ramachandran, V.S., Seshadri, S. (2018). Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the Framingham study. *JAMA Neurology*. 75(1):97-104.

**(The first and the second authors contributed equally to the paper).**

(IF 10.029, Rank=5/194 in, Clinical Neurology Q1,V)

64. #Kridin, K., Shihade, W., **Zelber-Sagi, S.** (2017). Mean Platelet Volume in Pemphigus Vulgaris. *Angiology*. 69(4):303-307.

(IF 3.085, Rank=28/63 in, Peripheral Vascular Disease Q2, V)

65. #Fliss-Isakov, N., **Zelber-Sagi, S.**, Webb, M., Halpern, Z., Kariv, R. (2017). Smoking habits are strongly associated with colonic polyps in a population-based case-control study. *Journal of Clinical Gastroenterology*. 33(4):800-806. **(The first and the second authors contributed equally to the paper).** (IF 3.163, Rank=28/79 in, Gastroenterology & Hepatology Q2, V)
66. Mlynarsky, L., **Zelber-Sagi, S.**, Miller, E., Kariv, R. (2017). Endoscopic resection of large colorectal adenomas - clinical experience of a tertiary referral center. *Colorectal Disease*. 20(5):391-398. (IF 2.689, Rank=56/197 in, Surgery Q2, V)
67. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D, Batat, E, Cohen, AD. (2017). Pemphigus and hematologic malignancies: A population-based study of 11,859 patients. *Journal of the American Academy of Dermatology*. 78(6):1084-1089. (IF 5.621, Rank=3/61 in, Dermatology Q1, V)
68. #Kridin, K., **Zelber-Sagi, S.**, Bergman, R. (2017). Mortality and Cause of Death in Patients with Pemphigus. *Acta Derm Venereol*. 97(5):607-611.
69. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, A. D. (2018). Association between pemphigus and neurologic diseases. *JAMA dermatology*. 154(3):281-285. (IF 7.995, Rank=1/66 in, Dermatology Q1, V)
70. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, A. D. (2018). Coexistent solid malignancies in pemphigus: A population-based study. *JAMA dermatology*. 154(4):435-440. (IF 7.995, Rank=1/66 in, Dermatology Q1, V)
71. #Kridin K., **Zelber-Sagi S.**, Bergman R. (2018). Risk factors for lethal outcome in patients with pemphigus: a retrospective cohort study. *European Journal of Dermatology*. 28(1):26-37. (IF 3.094, Rank=16/66 in, Dermatology Q1, V)
72. **Zelber-Sagi S.**, #Ivancovsky-Wajcman D., Isakov N. F., Webb M., Orenstein D., Shibolet O., Kariv R. (2018). High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. *Journal of Hepatology*. 68(6):1239-1246. (IF 18.946, Rank=3/84 in, Gastroenterology& Hepatology Q1, V)
73. #Fliss-Isakov, N., Kariv, R., Webb, M., #Ivancovsky, D., #Margalit, D., & **Zelber-Sagi, S.** (2018). Mediterranean dietary components are inversely associated with advanced colorectal polyps: A case-control study. *World Journal of Gastroenterology*, 24(24), 2617–2627. (IF 3.411, Rank=35/84 in, Gastroenterology& Hepatology Q2, V)
74. Schiavo, L., Busetto, L., Cesaretti, M., **Zelber-Sagi, S.**, Deutsch, L., Iannelli, A. (2018). Nutritional issues in patients with obesity and cirrhosis. *World Journal of*

*Gastroenterology*, 24(30):3330-3346. Review.  
(IF 3.411, Rank=35/84 in, Gastroenterology& Hepatology Q2, V)

75. Zaslavsky, O., **Zelber-Sagi, S.**, Shikany, J. M., Orchard, T., Wallace, R., Snetselaar, L., & Tinker, L. (2018). Anatomy of the Mediterranean Diet and Mortality Among Older Women with Frailty. *Journal of Nutrition in Gerontology and Geriatrics*, 17:1–13.  
(SJR 0.650, Rank= 53/110 in, Geriatrics and Gerontology Q2, V; 58/124 in, Nutrition and Dietetics Q2, V)
76. Katchman, H., **Zelber-Sagi, S.**, Baruch, R., Berman, G., Schwartz, I. F., Schwartz, D., Nakache, R., Goykhman, Y., Katz, p., Shibolet, O., Shashar, M., Grupper, A. (2018). Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. *Clinical Transplantation*, 32:e13240. (8 pages).  
(IF 1.667, Rank=17/25 in, Transplantation Q1, V)
77. Bar, N., Schwartz, N., Nissim, M., #Fliss-Isacov, N., **Zelber-Sagi, S.**, & Kariv, R. (2018). Barrett's esophagus with high grade dysplasia is associated with non-esophageal cancer. *World Journal of Gastroenterology*, 24(39), 4472-4481.  
(IF 3.411, Rank=35/84 in, Gastroenterology& Hepatology Q2, V)
78. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, AD. (2017). Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study. *Epidemiology and Psychiatric Sciences*, 28(2):191-198. (IF 5.684, Rank=15/142 in, Psychiatry Q1, V)
79. Kariv, R., Rosner, G., #Fliss-Isacov, N., Gluck, N., Strul, H., Elya, R., Caspi, S., Goldstein, A., Tulchinsky, H., **Zelber-Sagi, S.** (2017). Genotype phenotype associations of APC mutations with pouch adenoma in patients with familial adenomatous polyposis. *Diseases of the Colon & Rectum*, 53(2):e54-e60.  
(IF 3.616, Rank=26/200 in, Surgery Q1; Rank=26/80 in, Gastroenterology & Hepatology Q2, V)
80. #Kridin, K., **Zelber-Sagi, S.**, Comaneshter, D., Cohen, AD. (2017). Bipolar disorder associated with another autoimmune disease-pemphigus: A population-based study. *Canadian Journal of Psychiatry*, 63(7):474-480.  
(IF 3.612, Rank=42/142 in, Psychiatry Q1, V )
81. #Sherf-Dagan, S., Hod, K., Mardy-Tilbor, L., Gliksman, S., Ben-Porat, T., Sakran, N., **Zelber-Sagi S**, Goitein D, Raziell, A. (2018). The effect of pre-surgery information online lecture on nutrition knowledge and anxiety among bariatric surgery candidates. *Obesity Surgery*, 28(7):1876-1885.  
(IF 3.603, Rank=30/203 in, Surgery Q1, V )
82. Shenhar-Tsarfaty, S., #Sherf-Dagan, S., Berman, G., Webb M., Raziell A., Keidar A., Goitein D., Sakran N., Zwang E., Shapira I., Zeltser D., Berliner S., Rogowski O., Shibolet O., **Zelber-Sagi S.** (2018). Obesity-related acetylcholinesterase elevation is reversed following laparoscopic sleeve gastrectomy. *International*

- Journal of Obesity*, 43(2):297-305.  
(IF 4.514, Rank=12/86 in, Nutrition & Dietetics Q1, V )
83. #Kridin, K., Schwartz, N., Cohen, AD., **Zelber-Sagi, S.** (2018). Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios. *Journal of Dermatology*, 45(9):1094-1100.  
(IF 3.377, Rank=14/66 in, Dermatology Q1, V )
84. Azar, S., #Sherf-Dagan, S., Nemirovski, A., Webb, M., Raziell, A., Keidar, A., Goitein, D., Sakran, N., Shibolet, O., Tam, J., **Zelber-Sagi, S.** (2019). Circulating Endocannabinoids are reduced following bariatric surgery and associated with improved metabolic homeostasis in humans. *Obesity Surgery*, 29(1):268-276.  
(IF 3.603, Rank=30/203 in, Surgery Q1, V )
85. Merli, M., Berzigotti, A., **Zelber-Sagi, S.**, Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., Parés, A. (2019). EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *Journal of Hepatology*, 70(1):172-193.  
(IF 18.946, Rank=3/84 in, Gastroenterology& Hepatology Q1, V )
86. **Zelber-Sagi, S.** (2019). Minding the gap between clinical trials and treatment with the Mediterranean dietary pattern for patients with nonalcoholic fatty Liver disease. *Clinical Gastroenterology Hepatology*, 17(7):1248-1250. Invited Editorial.  
(IF 7.958, Rank=8/84 in, Gastroenterology& Hepatology Q1, V )
87. **Zelber-Sagi, S.**, #Zur, R., Thurm, T., Goldstein, A., Ben-Assuli, O., Chodick, G., Shibolet, O. (2019). Low serum vitamin D is independently associated with unexplained elevated ALT only among non-obese men in the general population. *Annals of Hepatology*, 18(4):578-584.  
(IF 1.895, Rank=68/84 in, Gastroenterology& Hepatology Q4, V )
88. #Ivancovsky-Wajcman, D., **Zelber-Sagi, S.**, Fliss Isakov, N., Webb, M., Zemel, M., Shibolet, O., Kariv, R. (2019). Serum Soluble Receptor for AGE (sRAGE) levels Are associated with unhealthy lifestyle and nonalcoholic fatty liver disease. *Clinical Translational Gastroenterology*, 22;10(5):1-10.  
(IF 4.803, Rank=20/84 in, Gastroenterology& Hepatology Q1, V )  
**(The first and the second authors contributed equally to the paper).**
89. Sherf-Dagan, S., **Zelber-Sagi, S.**, Buch, A., Bar, N., Webb, M., Sakran, N., Raziell, A., Goitein, D., Keidar, A., Shibolet, O. (2019). Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy. *Obesity Surgery*, 29(12):3833-3841.  
(IF 3.603, Rank=30/203 in, Surgery Q1, V )
90. #Ivancovsky-Wajcman, D., Fliss-Isakov, N., Salomone, F., Webb, M., Shibolet, O., Kariv, R., **Zelber-Sagi, S.** (2019). Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. *Digestive and Liver Disease*, 51(12):1698-1705.



(IF 3.037, Rank=42/84 in, Gastroenterology and Hepatology Q2, V )

91. Ryan, MC., **Zelber-Sagi, S.** (2019). Hepatic fat: Pathogenic trigger or passenger? *Journal of Hepatology*, 71(2):249-251. Invited Editorial.  
(IF 18.946, Rank=3/84 in, Gastroenterology& Hepatology Q1, V)
92. Weinstein, G., Davis-Plourde, K., Himali, JJ., **Zelber-Sagi, S.**, Beiser, AS., Seshadri, S. (2019). Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. *Liver International*, 39(9):1713-1721.  
(IF 5.542, Rank=16/84 in, Gastroenterology& Hepatology Q1, V)
93. Fliss-Isakov, N., Kariv, R., Webb, M., #Ivancovsky-Wajcman, D., Zaslavsky, O., Margalit, D., Shibolet, O., **Zelber-Sagi, S.** (2019). A healthy lifestyle pattern has a protective association with colorectal polyps. *European Journal of Clinical Nutrition*, 74(2):328-337.  
(IF 3.114, Rank=37/86 in, Nutrition & Dietetics Q2, V)
94. Fliss-Isakov, N., Grosso, G., Salomone, F., Godos, J., Gavalno F., #Ivancovsky-Wajcman D., Shibolet O., Kariv R., **Zelber-Sagi, S.** (2019). High intake of phenolic acid is associated with reduced risk of colorectal adenomas among smokers. *Clinical Gastroenterology Hepatology*, 18(8):1893-1895.e3.  
(IF 7.958, Rank=8/84 in, Gastroenterology& Hepatology Q1, V)
95. Nouredin, M., **Zelber-Sagi, S.**, Wilkens, L. R., Porcel, J., Boushey, C. J., Le Marchand, L., Rosen HR, Setiawan, V. W. (2019). Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the Multiethnic Cohort. *Hepatology*, 71(6):1940-1952.  
(IF 14.971, Rank= 5/84 in, Gastroenterology& Hepatology Q1, V)
96. Salomone, F., #Ivancovsky-Wajcman, D., Fliss-Isakov, N., Webb, M., Grosso, G., Godos, J., Galvano, F., Shibolet, O., Kariv, R., **Zelber-Sagi, S.** (2020). Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease. *JHEP Reports*, 2(2):100069 (7 pages).  
(IF, Rank= not yet determined in, Gastroenterology& Hepatology Q not yet determined, V)
97. GBD 2017 Cirrhosis Collaborators, **Zelber-Sagi, S.** (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*, 5(3):245–266.  
(IF 12.856, Rank=6/84 in, Gastroenterology& Hepatology Q1, V)
98. Eslam, M., Newsome, PN., Anstee, QM., Targher, G., Gomez, MR., **Zelber-Sagi S.**, Wong, VW., Dufour, JF., Schattenberg, J., Arrese, M, Valenti, L., Shiha, G., Tiribelli, C., Yki-Järvinen, H., Fan, JG., Gronbaek, H., Yilmaz, Y., Cortez-Pinto, H., Oliveira, CP., Bedossa, P., Adams, LA., Zheng, MH., Fouad, Y., Chan, WK., Mendez-Sanchez, N., Ahn, SH., Castera, L., Bugianesi, E., Ratziu, V., George, J. (2020). A new

definition for metabolic associated fatty liver disease: an international expert consensus statement. *Journal of Hepatology*, 73(1):202-209. Consensus statement.

(IF 18.946, Rank=3/84 in, Gastroenterology & Hepatology Q1, V)

99. Deutsch, L., Houri, I., Ben-Ari, Z., Shlomai, A., Veitsman, E., Cohen-Ezra, O., Issachar, A., Mor, O., Gozlan, Y., Bruck, R., Menachem, Y., **Zelber-Sagi S.**, Katchman, H., Shibolet, O. (2020). Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial. *BMC Infect Dis*, 20(1):264. (10 pages).

(IF 2.565, Rank=48/89 in, Infectious Diseases Q3, V)

100. Hayek S, Derhy S, Smith ML, Towne SD Jr, **Zelber-Sagi S.** (2020). Patient satisfaction with primary care physician performance in a multicultural population. *Isr J Health Policy Res*, 9(1):13. (9 pages).

(IF 1.662, Rank=78/164 in, Public, Environmental & Occupational Health Q2, V)

101. #Sarbagili-Shabat, C., **Zelber-Sagi, S.**, Fliss Isakov, N., Ron, Y., Hirsch, A., Maharshak, N. (2020). Development and validation of processed foods questionnaire (PFQ) in adult inflammatory bowel diseases patients. *Eur J Clin Nutr*, 74(12):1653-1660. (IF 3.114, Rank= 37/87 in, Nutrition & Dietetics Q2, V)

102. Lazarus, JV, Colombo, M, Cortez-Pinto, H, Huang, TT, Miller, V, Ninburg, M, Schattenberg, JM, Seim, L, Wong, VWS, **Zelber-Sagi, S.** (2020). NAFLD - sounding the alarm on a silent epidemic. *Nat Rev Gastroenterol Hepatol*. 17(7):377-379. Comment. (IF 23.570, Rank=1/84 in, Gastroenterology & Hepatology Q1, V)

103. **Zelber-Sagi, S.**, #Ivancovsky-Wajcman, D., Fliss Isakov, N., Hahn, M., Webb, M., Shibolet, O., Kariv, R., Tirosh, O. (2020). Serum Malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. *Antioxidants*, 9(7):578. (15 pages).

(IF 5.014, Rank=56/297 in, Biochemistry & Molecular Biology. 7/61 in, Chemistry, Medicinal. 10/139 in, Food Science & Technology Q1, V)

104. Schonmann, Y., Yeshua, H., Bentov, I., **Zelber-Sagi, S.** (2020). Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. *Digestive and liver disease*, 3(1):79-85.

(IF 3.570, Rank=37/88 in, Gastroenterology & Hepatology Q2, V)

105. Gotlieb, N., Schwartz, N., **Zelber-Sagi, S.**, Chodick, G., Shalev, V., & Shibolet, O. (2020). Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis. *World journal of gastroenterology*, 26(38):5849–5862.

(IF 3.665, Rank=35/88 in, Gastroenterology & Hepatology Q2, V)

106. Fliss-Isakov, N., **Zelber-Sagi, S.**, #Ivancovsky-Wajcman, D., Shibolet, O., & Kariv, R. (2020). Ultra-Processed Food Intake and Smoking Interact in Relation with Colorectal Adenomas. *Nutrients*, 12(11):3507. (15 pages).

(The first and the second authors contributed equally to the paper)

(IF 4.546, Rank=17/89 in, Nutrition & Dietetics Q1, V)

107. Kridin, K., Jones, V. A., Patel, P. M., **Zelber-Sagi, S.**, Hammers, C. M., Damiani, G., Amber, K. T., & Cohen, A. D. (2020). Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study. *Immunologic research*, 68(6):373–378. (IF 2.507, Rank=112/159 in, Immunology Q3, V)
108. Goldman, O., Ben-Assuli, O., Rogowski, O., Zeltser, D., Shapira, I., Berliner, S., **Zelber-Sagi, S.**, & Shenhar-Tsarfaty, S. (2021). Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. *Journal of medical systems*, 45(2):22. (12 pages). (IF 3.058, Rank=23/102 in, Health Care Science & Service Q1, V)
109. Hagström, H., Adams, L. A., Allen, A. M., Byrne, C. D., Chang, Y., Grønbaek, H., Ismail, M., Jepsen, P., Kanwal, F., Kramer, J., Lazarus, J. V., Long, M. T., Loomba, R., Newsome, P. N., Rowe, I. A., Ryu, S., Schattenberg, J. M., Serper, M., Sheron, N., Simon, T. G., Tapper, E. B., Wild, S., Wong, V. W., Yilmaz, Y., **Zelber-Sagi, S.**, Åberg, F. (2021). Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. *Hepatology*, 74(1):474-482. Consensus statement. (IF 14.679, Rank=6/88 in, Gastroenterology & Hepatology Q1, V)
110. Auckley, E. D., Bentov, N., **Zelber-Sagi, S.**, Jeong, L., Reed, M. J., Bentov, I. (2021). Frailty status as a potential factor in increased postoperative opioid use in older adults. *BMC geriatrics*, 21(1):189. (10 pages). (IF 3.077, Rank= 6/36 in, Gerontology Q1, V)
111. **Zelber-Sagi, S.**, #Ivancovsky-Wajcman, D., Rabinowich, L., Bentov, I., Deutsch, L. (2021). Nutritional evaluation and treatment of the cirrhotic patient. *Clinics in Liver Disease*, 25(2):373-392. **Invited review.** (IF 4.623, Rank=22/88 in, Gastroenterology & Hepatology Q1, V)
112. Lazarus, J. V., Palayew, A., Carrieri, P., Ekstedt, M., Marchesini, G., Novak, K., Ratziu, V., Romero-Gómez, M., Tacke, F., **Zelber-Sagi, S.**, Cortez-Pinto, H., Anstee, Q. M. (2021). European' NAFLD Preparedness Index - 'Is Europe ready to meet the challenge of fatty liver disease? *JHEP reports*, 3(2):100234. (8 pages). (IF, Rank= not yet determined in, Gastroenterology& Hepatology Q not yet determined, V)
113. Salomone, F., Currenti, W., Magri, G., Boškoski, I., **Zelber-Sagi, S.**, Galvano, F. (2021). Effects of intragastric balloon in patients with Non-Alcoholic Fatty Liver Disease and advanced fibrosis. *Liver International*, 41(9):2112-2116. (IF 5.542, Rank=16/84 in, Gastroenterology& Hepatology Q1, V)
114. Lazarus, J. V., Kakalou, C., Palayew, A., Karamanidou, C., Maramis, C., Natsiavas, P., Picchio, C. A., Villota-Rivas, M., **Zelber-Sagi, S.**, Carrieri, P. (2021). A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH, and obesity. *Liver International*, 41(10):2295-2307. (IF 5.828, Rank=16/84 in, Gastroenterology& Hepatology Q1, V)

115. **Zelber-Sagi, S.** (2021). Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. *Seminars in Liver Disease*, 41(03):248-262. **Invited review.** (IF 4.457, Rank=25/88 in, Gastroenterology & Hepatology Q2, V).
116. Towne, S. D., Jr, Liu, X., Li, R., Smith, M. L., Maddock, J. E., Tan, A., Hayek, S., **Zelber-Sagi, S.**, Jiang, X., Ruan, H., & Yuan, Z. (2021). Social and Structural Determinants of Health Inequities: Socioeconomic, Transportation-Related, and Provincial-Level Indicators of Cost-Related Forgone Hospital Care in China. *International journal of environmental research and public health*, 18(11):6113. (11 pages). (IF 3.390, Rank=41/176 in, Public, Environmental & Occupational health Q1, V).
117. #Ivancovsky-Wajcman, D., Fliss-Isakov, N., Webb, M., Bentov, I., Shibolet, O., Kariv, R., **Zelber-Sagi, S.** (2021). Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. *Liver international*, 41(11):2635-2645. (IF 5.828, Rank=16/84 in, Gastroenterology& Hepatology Q1, V)
118. Lazarus, J. V., Anstee, Q. M., Hagström, H., Cusi, K., Cortez-Pinto, H., Mark, H. E., Roden, M., Tsochatzis, E. A., Wong, V. W., Younossi, Z. M., **Zelber-Sagi, S.**, Romero-Gómez, M., & Schattenberg, J. M. (2021). Defining comprehensive models of care for NAFLD. *Nature reviews Gastroenterology & hepatology*, 18(10):717-729. (IF 46.802, Rank=1/92 in, Gastroenterology& Hepatology Q1, V)
119. #Zittan, E., Steinhart, AH., Aran, H., Milgrom, R., Gralnek, IM., **Zelber-Sagi, S.**, Silverberg, MS . (2021). The Toronto IBD Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients. *J Crohns Colitis*. (10 pages). (IF 9.071, Rank=14/92 in, Gastroenterology& Hepatology Q1, V)  
**(The two last authors contributed equally to the paper).**
120. Abu-Halaka, D., Gover, O., Rauchbach, E., **Zelber-Sagi, S.**, Schwartz, B., & Tirosh, O. (2021). Whole body metabolism is improved by hemin added to high fat diet while counteracted by nitrite: a mouse model of processed meat consumption. *Food & function*, 12(18):8326-8339. (IF 5.396, Rank=22/143 in, Food Science & Technology Q1, V)
121. Bashkin, O., Dopelt, K., Mor, Z., Leighton, L., Otok, R., Duplaga, M., MacLeod, F., De Nooijer, J., Neumark, Y., Paillard-Borg, S., Tulchinsky, T., **Zelber-Sagi, S.**, & Davidovitch, N. (2021). The Future Public Health Workforce in a Changing World: A Conceptual Framework for a European-Israeli Knowledge Transfer Project. *International journal of environmental research and public health*, 18(17), 9265. (9 pages).

(IF 3.390, Rank=42/176 in, Public, Environmental & Occupational Health SSCI Q1, V)

122. Lazarus, JV., Mark, HE., Anstee, QM., Arab, JP., Batterham, RL., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, MA., Francque, S., George, J., Hagström, H., Huang, TT., Ismail, MH., Kautz, A., Sarin, SK., Loomba, R., Miller, V., Newsome, PN., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, JM., Tsochatzis, EA., Valenti, L., Wong, VW., Yilmaz, Y., Younossi, ZM., **Zelber-Sagi, S.** (2021). Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. Ahead of print. (19 pages). (IF 46.802, Rank=1/92 in, Gastroenterology& Hepatology Q1, V)
123. Francque, SM., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, JV., **Zelber-Sagi, S.**, Hallsworth, K., Busetto, L., Frühbeck, G., Dicker, D., Woodward, E., Korenjak, M., Willemsse, J., Koek, GH., Vinker, S., Ungan, M., Mendive, JM., Lionis, C. (2021). Non-alcoholic fatty liver disease: A patient guideline. *JHEP Rep*, 3(5):100322. (39 pages). (IF, Rank= not yet determined in, Gastroenterology& Hepatology Q not yet determined, V)
124. Karlsen, T. H., Sheron, N., **Zelber-Sagi, S.**, Carrieri, P., Geoffrey Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., Manns, M. P., (2022) The EASL-Lancet Commission: Protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet*, 399(10319):61-116. (**Special topic of the EASL-Lancet Commission**). (IF 79.321, Rank=2/169 in, Medicine, general & internal Q1, V)
125. Lazarus, J. V., Mark, H. E., Colombo, M., Demaio, S., Dillon, J. F., George, J., Hagström, H., Hocking, S., Lee, N., Nieuwenhuijsen, M. J., Rinella, M. E., Romero-Gomez, M., Soriano, J. B., Schattenberg J. M., Tacke, F., Tsochatzis, E. A., Valenti, L., **Zelber-Sagi, S.**, Ashworth Dirac, M., Huang, T. T. (2021). Sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. *Aliment Pharmacol Ther*. Online ahead of print (10 pages). (IF 8.171, Rank=15/92 in, Gastroenterology& Hepatology Q1, V)
126. Lazarus, JV., Mark, HE., Villota-Rivas, M., Palayew, A., Carrieri ,P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., Novak, K., Ocama, P., Ratziu, V., Razavi, H., Romero-Gómez, M., Silva, M., Spearman, CW., Tacke, F., Tsochatzis, EA., Yilmaz, Y., Younossi, ZM., Wong, VW., **Zelber-Sagi, S.**, Cortez-Pinto, H., Anstee, QM.(2021). The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? *J Hepatol*, 21:S0168-8278. (IF 18.946, Rank=3/84 in, Gastroenterology& Hepatology Q1, V)

127. **Zelber-Sagi, S.**, Nouredin, M., Shibolet, O. (2021). Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations. *Cancers*,14(1),103. (IF 6.639, Rank=51/242 in, Oncology Q1, V)
128. Peck-Radosavljevic, M., Burra, P., Ferret, MB., Fracasso, P., Ricciardiello, L., Seufferlein, T., Van Hooetegem, P., van Leerdam, M., **Zelber-Sagi, S.** (2021). UEG Public Affairs Committee. COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. *United European Gastroenterol J*,9(9):1091-1095. (IF 4.623, Rank=35/92 in, Gastroenterology& Hepatology Q2, V)
129. Ben-Assuli, O., Jacobi, A., Goldman, O., Shenhar-Tsarfaty, S., Rogowski. O., Zeltser, D., Shapira, I., Berliner, S., **Zelber-Sagi, S.** (2022). Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. *J Biomed Inform*,7,126. (IF 6.317, Rank=3/30 in, Medical Informatics Q1, V)
130. Weinstein, G., Vered, S., #Ivancovsky-Wajcman, D., Springer, RR., Heymann, A., **Zelber-Sagi, S.**, Shahar, DR., Schnaider Beerli, M. (2022) Consumption of ultra-processed food and cognitive decline among older adults with type-2 diabetes. *J Gerontol A Biol Sci Med Sci*. (IF 6.053, Rank=1/36 in, Gerontology Q1, V)
131. Méndez-Sánchez, N., Bugianesi, E., Gish, RG., Lammert, F., Tilg, H., Nguyen, MH., Sarin, SK., Fabrellas, N., **Zelber-Sagi, S.**, Fan, JG., Shiha, G., Targher, G., Zheng, MH., Chan, WK., Vinker, S., Kawaguchi, T., Castera, L., Yilmaz, Y., Korenjak, M., Spearman, CW., Ungan, M., Palmer, M., El-Shabrawi, M., Gruss, HJ., Dufour, JF., Dhawan, A., Wedemeyer, H., George, J., Valenti, L., Fouad, Y., Romero-Gomez, M., Eslam, M. (2022) Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. *Lancet Gastroenterol Hepatol*. (5):388-390. (IF 18.486, Rank=5/92 in, Gastroenterology& Hepatology Q1, V)
132. Weinstein, G., O'Donnell, A., Davis-Plourde, K., **Zelber-Sagi, S.**, Ghosh, S., DeCarli, CS., Thibault, EG., Sperling, RA., Johnson, KA., Beiser, AS., Seshadri, S. (2022) Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid- $\beta$  and Tau Pathology in Middle-Aged Adults: The Framingham Study. *J Alzheimers Dis*. (IF 4.472, Rank=94/273 in, Neurosciences Q2, V)
133. #Rein, M., Ben-Yacov, O., Godneva, A., Shilo, S., Zmora, N., Kolobkov, D., Cohen-Dolev, N., Wolf, BC., Kosower, N., Lotan-Pompan, M., Weinberger, A., Halpern, Z., **Zelber-Sagi, S.**, Elinav, E., Segal E. (2022) Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial. *BMC Med*. 20(1):56. (IF 8.775, Rank=13/167 in, Medicine, General & Internal Q1, V)
134. **Zelber-Sagi, S.**, #Sol Grinshpan, L., #Ivancovsky-Wajcman, D., Goldenshluger ,A., Gepner, Y. (2022). One size does not fit all; practical, personal tailoring of the diet to NAFLD patients. *Liver Int*. (IF 5.828, Rank=16/84 in, Gastroenterology& Hepatology Q1, V)

135. Moran-Lev, H., Cohen, S., **Zelber-Sagi, S.**, Mazkeret Mayer, E., Anafy, A., Yerushalmy-Feler, A., Lubetzky, R. (2022). Effect of Coffee and Tea Consumption on Adolescent Weight Control: An Interventional Pilot Study. *Child Obes*, (IF 2.992, Rank=39/129 in, Pediatrics Q2, V)
136. **Zelber-Sagi, S.**, O'Reilly-Shah, VN., Fong, C., Ivancovsky-Wajcman, D., Reed, MJ., Bentov, I. (2022) Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. *Anesth Analg*, (IF 5.178, Rank=7/33 in, Anesthesiology Q1, V)
137. Dufour, JF., Anstee, QM., Bugianesi, E., Harrison, S., Loomba, R., Paradis, V., Tilg, H., Wong, VW., **Zelber-Sagi S.** (2022) Current therapies and new developments in NASH. *GUT*, 0:1-12. (IF 23.059, Rank=in, Q1, V)
138. Buch, A., Yeshurun, S., Cramer, T., Baumann, A., Sencelsky, Y., **Zelber Sagi, S.**, Serebro, M., Greenman, Y., Mor, M., Eldor, R. (2022). The effects of metabolism tracker device (Lumen®) usage on metabolic control in adults with prediabetes: pilot clinical trial. *Obes Facts*,
139. Ivancovsky-Wajcman, D., Fliss-Isakov, N., Grinshpan, LS., Salomone, F., Lazarus, JV., Webb, M., Shibolet, O., Kariv, R., **Zelber-Sagi, S.** (2022). High Meat Consumption Is Prospectively Associated with the Risk of Non-Alcoholic Fatty Liver Disease and Presumed Significant Fibrosis. *Nutrients*, 14(17).
140. Wong, VWS., **Zelber-Sagi, S.**, Cusi, K., Carrieri, P., Wright, E., Crespo, J., Lazarus JV. (2022). Management of NAFLD in primary care settings. *Liver Int*, 42(11):2377-2389.
141. Burra, P., Arvanitakis, M., Dias, JA., Bretthauer, M., Dugic, A., Hartmann, D., Michl, P., Seufferlein, T., Torres, J., Törnblom, H., van Leerdam, ME., **Zelber-Sagi, S.**, Botos A. (2022). UEG position paper: Obesity and digestive health. *United European Gastroenterol J*.
142. Schattenberg, JM., Allen, AM., Jarvis, H., **Zelber-Sagi, S.**, Cusi, K., Dillon, JF., Caussy, C., Francque, SM., Younossi, Z., Alkhoury, N., Lazarus JV. (2023). A multistakeholder approach to innovations in NAFLD care. *Commun Med (Lond)*, 3;3(1):1.
143. Minciună, I., Gallage, S., Heikenwalder, M., **Zelber-Sagi, S.**, Dufour, JF. (2023). Intermittent fasting-the future treatment in NASH patients? *Hepatology*.
144. Iruzubieta, P., Bataller, R., Arias-Loste, MT., Arrese, M., Calleja, JL., Castro-Narro, G., Cusi, K., Dillon, JF., Martínez-Chantar, ML., Mateo, M., Pérez, A., Rinella, ME., Romero-Gómez, M., Schattenberg, JM., **Zelber-Sagi, S.**, Crespo, J., Lazarus, JV. (2023). Research Priorities for Precision Medicine in NAFLD. *Clinics of liver disease*, 27(2):535-551.
145. Rinella, ME., Lazarus, JV., Ratziu, V., Francque, SM., Sanyal, AJ., Kanwal, F., Romero, D., Abdelmalek, MF., Anstee, QM., Arab, JP., Arrese, M., Bataller, R.,

- Beuers, U., Boursier, J., Bugianesi, E., Byrne, C., Castro-Narro, GE., Chowdhury, A., Cortez-Pinto, H., Cryer, D., Cusi, K., El-Kassas, M., Klein, S., Eskridge, W., Fan, J., Gawrieh, S., Guy, CD., Harrison, SA., Kim, SU., Koot, B., Korenjak, M., Kowdley, K., Lacaille, F., Loomba, R., Mitchell-Thain, R., Morgan, TR., Powell, E., Roden, M., Romero-Gómez, M., Silva, M., Singh, SP., Sookoian, SC., Spearman, CW., Tiniakos, D., Valenti, L., Vos, MB., Wai-Sun Wong, V., Xanthakos, S., Yilmaz, Y., Younossi, Z., Hobbs, A., Villota-Rivas, M., Newsome, PN. NAFLD Nomenclature consensus group. (2023). A Multi-Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. *Journal of Hepatology*.
146. Lazarus, JV., Mark, HE., Allen, AM., Arab, JP., Carrieri, P., Nouredin, M., Alazawi, W., Alkhoury, N., Alqahtani, SA., Arrese, M., Bataller, R., Berg, T., Brennan, PN., Burra, P., Castro-Narro, GE., Cortez-Pinto, H., Cusi, K., Dedes, N., Duseja, A., Francque, SM., Hagström, H., Huang, TT., Wajcman, DI., Kautz, A., Kopka, CJ., Krag, A., Miller, V., Newsome, PN., Rinella, ME., Romero, D., Sarin, SK., Silva, M., Spearman, CW., Tsochatzis, EA., Valenti, L., Villota-Rivas, M., **Zelber-Sagi, S.**, Schattenberg, JM., Wong, VW., Younossi, ZM; Healthy Livers, Healthy Lives Collaborators. (2023). A Global Research Priority Agenda to Advance Public Health Responses to Fatty Liver Disease. *Journal of Hepatology*.
147. Allen, AM., Younossi, ZM., Tsochatzis, EA., Alazawi, W., **Zelber-Sagi, S.**, Arab, JP., Cusi, K., Lazarus, JV. (2023). Measuring NAFLD Models of Care. *Nature reviews Gastroenterology & Hepatology*.
148. Younossi, ZM., **Zelber-Sagi, S.**, Henry, L., Gerber, LH. (2023). Lifestyle Interventions in Nonalcoholic Fatty Liver Disease. *Nature reviews gastroenterology & hepatology*.
149. Lazarus, JV., Han, H., Mark, HE., Alqahtani, SA., Schattenberg, JM., Soriano, JB., White, TM., **Zelber-Sagi, S.**, Dirac, MA. (2023). The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories. GBD Fatty Liver Disease Sustainable Development Goal Collaborators. *Hepatology*,78(3):911-928.
150. Lazarus, JV., Mark, HE., Allen, AM., Arab, JP., Carrieri, P., Nouredin, M., Alazawi, W., Alkhoury, N., Alqahtani, SA., Anstee, QM., Arrese, M., Bataller, R., Berg, T., Brennan, PN., Burra, P., Castro-Narro, GE., Cortez-Pinto, H., Cusi, K., Dedes, N., Duseja, A., Francque, SM., Gastaldelli, A., Hagström, H., Huang, TTK., Ivancovsky Wajcman, D., Kautz, A., Kopka, CJ., Krag, A., Newsome, PN., Rinella, ME., Romero, D., Sarin, SK., Silva, M., Spearman, CW., Terrault, NA., Tsochatzis, EA., Valenti, L., Villota-Rivas, M., **Zelber-Sagi, S.**, Schattenberg, JM., Wong, VW., Younossi, ZM. (2023). A global action agenda for turning the tide on fatty liver disease. Healthy Livers, Healthy Lives Collaborators. *Hepatology*.
151. Hadeifi, A., Arvanitakis, M., Trépo, E., **Zelber-Sagi, S.** (2023). Dietary strategies in non-alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review. *United European Gastroenterol J*,11(7):663-689.
152. Dopelt, K., Shevach, I., Vardimon, OE., Czabanowska, K., De Nooijer, J., Otok, R., Leighton, L., Bashkin, O., Duplaga, M., Levine, H., MacLeod, F., Malowany, M.,



Okenwa-Emegwa, L., **Zelber-Sagi, S.**, Davidovitch, N., Barach, P. (2023). Simulation as a key training method for inculcating public health leadership skills: a mixed methods study. *Front Public Health*,6(11).

153. Ivancovsky-Wajcman, D., Brennan, PN., Kopka, CJ., **Zelber-Sagi, S.**, Younossi, ZM., Allen, AM., Flórez, KR., Lazarus, JV. (2023). Integrating social nutrition principles into the treatment of steatotic liver disease. *Commun Med (Lond)*,3(1):165.

154. Brennan, PN., **Zelber-Sagi, S.**, Allen, AM., Dillon, JF., Lazarus, JV. (2023). Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm. *Gut*.

155. Romero-Gómez, M., **Zelber-Sagi, S.**, Martín, F., Bugianesi, E., Soria, B. (2023). Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention. *BMJ*.

### **Letters to the Editor**

1. **+Zelber-Sagi, S.**, Ben-Assuli, O., Rabinowich, L., Shalev, V., Shibolet, O., Gabriel, C. (2016). Reply to: "The Relationship between Serum Uric Acid Levels and NAFLD". *Liver International*. 36(5):769-70. **A response to comments made on article D30.** (IF 4.470, Rank=13/79 in, Gastroenterology& Hepatology Q1, V)

2. **Zelber-Sagi, S.**, Schonmann, Y., Yeshua, H., Bentov, I. (2021). Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?". *Dig Liver Dis*, 53(3):385-386. **A response to comments made on article D103.** (IF 3.570, Rank=37/88 in, Gastroenterology & Hepatology Q2, V)

### **E. Articles or Chapters in Scientific Books** (which are not Conference Proceedings)

### **Published**

1. **Zelber-Sagi, S.** Diet and Lifestyle changes as treatment for NAFLD. In: Liver metabolism and fatty liver disease. Florida: *Taylor & Francis Group* 2013. Pages: 12.

2. **Zelber-Sagi, S.**, Yeshua, C., Shibolet, O., & Oren R. (2014). The fatty liver: association with type 2 Diabetes and methods of treatment. In: A. Choen., O. Mosenzone., & I. Raz (Eds.), *The Guide for the treatment of diabetes* (pp. 185-196). Medical Group, The National Council of Diabetes and The Ministry of Health: Tel – Aviv.
3. **Zelber-Sagi, S.** Nutrition Role in Liver Protection and Damage. (2014). In: Tirosh., O. (Ed.), *Liver Metabolism and Fatty Liver Disease*. (PP.209-230). CRC Press, the Taylor & Francis Group, 2014.
4. **Zelber-Sagi, S.**, Yeshua, C., Shibolet, O. (2017). The fatty liver: association with type 2 Diabetes and methods of treatment. In: A. Choen. & I. Raz (Eds.), *The Guide for the treatment of diabetes* (pp. 291-307). Medical Group, The National Council of Diabetes and The Ministry of Health: Tel – Aviv.
5. **Zelber-Sagi, S.**, Yeshua, C., Margalit, M., Shibolet, O. (2019). The fatty liver: association with type 2 Diabetes and methods of treatment. In: A. Choen. & I. Raz (Eds.), *The Guide for the treatment of diabetes* (pp. 273-295). Medical Group, The National Council of Diabetes and The Ministry of Health: Tel – Aviv.
6. Margalit, M., Yeshua, H., Gotlieb, N., **Zelber-Sagi, S.** (2020). Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. In: M. Romero-Gomez (Eds.), *NAFLD and NASH* (pp. 11-28). Springer Nature.
7. **Zelber-Sagi, S.**, Yeshua, C., #Ivancovsky-Wajcman, D., Margalit, M., Shibolet, O. (2022). The fatty liver: association with type 2 Diabetes and methods of treatment. In: A. Choen. & I. Raz (Eds.), *The Guide for the treatment of diabetes* (pp.). Medical Group, The National Council of Diabetes and The Ministry of Health: Tel – Aviv.
8. **Zelber-Sagi, S.**, Yeshua, C., #Ivancovsky-Wajcman, D. (2023). The fatty liver: association with type 2 Diabetes and methods of treatment. In: A. Choen. & I. Raz (Eds.), *The Guide for the treatment of diabetes* (pp. a head of print). Medical Group, The National Council of Diabetes and The Ministry of Health: Tel – Aviv.

#### F. Articles in Conference Proceedings

##### Published

1. **Zelber Sagi S.** Diet and Lifestyle changes as a treatment for NAFLD. In: *The 10th Liver Therapy meeting*. Barcelona: Elsevier Doyma 2013. 71-76.
2. **Zelber Sagi S.** Evidence for weight management by nutrition for the progression of NAFLD, metabolic or cardiovascular disease. In: *European Association for the Study of the Liver postgraduate course international liver congress book*. Amsterdam: European Association for the Study of the Liver postgraduate course

International Liver Congress 2017. 150-157.

3. **Zelber Sagi S.** Assessment and relevance of sarcopenia and frailty. In: *EASL postgraduate course international liver congress book*. Vienna: European Association for the Study of the Liver postgraduate course International Liver Congress 2019.
4. **Zelber Sagi S.** Which diet should I be taking? In: *European Association for the Study of the Liver postgraduate course international liver congress book*. London: European Association for the Study of the Liver postgraduate course International Liver Congress 2021. 68-78.
5. **Zelber Sagi S.** Diet – what does it take? In: *European Association for the Study of the Liver postgraduate course international liver congress book*. London: European Association for the Study of the Liver postgraduate course International Liver Congress 2021. 158-164.

#### **G. Entries in Encyclopedias**

None

#### **H. Other Scientific Publications**

#### **Abstracts Published**

1. **Zelber-Sagi, S.**, Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M., Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2004). A double-blind randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver disease. *Hepatology*. (40) 1069.
2. **Zelber-Sagi, S.**, Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M., Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2005). Does weight loss improve liver histopathology in patients with NAFLD? *Journal of Hepatology*. Sup. (42) 705.
3. Kessler, A., Levy, Y., Roth, A., **Zelber-Sagi, S.**, Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2005). Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. *Hepatology* (42) 1084.
4. **Zelber-Sagi, S.**, Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005). Is NAFLD an independent predictor of the metabolic syndrome? *Hepatology* (42) 1069.
5. **Zelber-Sagi, S.**, Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005). Hyperinsulinemia is an independent predictor of elevated serum ALT levels even

- after adjustment to NAFLD and liver histology. *Hepatology* (42) 1081.
6. **Zelber-Sagi, S.**, Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2006). Serum ALT is not a reliable screening tool for NAFLD in the general population. *Journal of Hepatology. Sup.* 2(44) 727.
  7. **Zelber-Sagi, S.**, Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M., Halpern, Z., Oren, R. (2007). The association between NAFLD and long term nutritional intake, a population based study. *Journal of Hepatology. Sup.* 1(46) 291.
  8. **Zelber-Sagi, S.**, Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M., Halpern, Z., Oren, R. (2007). Role of physical activity in non-alcoholic fatty liver disease (NAFLD): A population based study. *Hepatology* (46) 1150.
  9. **Zelber-Sagi, S.**, Webb, M., Ratziu, V., Poynard, T., Halpern, Z., Oren, R. (2008). A comparison between the hepatorenal ultrasound index and steatotest for the non-invasive quantification of liver steatosis. *Journal of Hepatology. Sup.* 2(48) 368.
  10. **Zelber-Sagi, S.**, Yeshua, H., Halpern, Z., Oren, R. (2009). Discordance between three successive Fibroscan measurements mirrors the variability of liver fibrosis. *Journal of Hepatology. Sup.* 1(50) 375.
  11. **Zelber-Sagi, S.**, Ratziu, V., Zvibel, I., Goldiner, I., Nitzan-Kaluski, D., Blendis, L., Gilles, M., Halpern, Z., Oren, R. (2009). Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A study in the general population. *Journal of Hepatology. Sup.* 1(50) 375.
  12. **Zelber-Sagi, S.**, Webb, M., Leshno, M., Blendis, L., Yeshua, H., Ratziu, V., Halpern, Z., Oren, R. (2010). A comparison of fatty liver index with three non-invasive methods for the detection and Quantification of liver steatosis: Regular ultrasound, hepatorenal ultrasound index and steatotest. *Journal of Hepatology. Sup.* 1(52) 158.
  13. **Zelber-Sagi, S.**, Webb, M., Leshno, M., Blendis, L., Isaak Winocur, M., Yeshua, H., Halpern, Z., Oren, R. (2010). The hepatorenal ultrasound index is correlated with obesity, ALT, insulin and adipocytokines. *Journal of Hepatology. Sup.* 1(52) 158.
  14. **Zelber-Sagi, S.**, Lotan, R., Webb, M., Halpern, Z., Oren, R. (2011). Incidence and regression rates of NAFLD in seven years follow up of a cohort from the general population. *Journal of Hepatology. Sup.* 1(54) 351.
  15. **Zelber-Sagi, S.**, Lotan, R., Shibolet, O., Webb, M, Buch, A., Nitzan-Kaluski, D., Halpern Z., Santo, E., Oren R. (2012). NAFLD independently predicts type-2 diabetes and pre-diabetes during a seven-year prospective follow-up. *Journal of Hepatology. Sup.* 2(56) 526.
  16. **Zelber-Sagi, S.**, Toker, S., Shirom, A., Melamed, S., Berliner, S., Shapira, I., Halpern, Z., Santo, E., Shibolet O. (2012). Elevated Alanine transaminase independently predicts new onset of depression in employees undergoing health screening

examinations. *Journal of Hepatology*. Sup. 2(56) 526.

17. **Zelber-Sagi, S.**, Buch A., Yeshua H., Vaisman N., Harari, G., kiss O., Webb, M., Fliss, N., Halpern, Z., Santo, E., Oren, R., Shibolet O. (2012). The effect of resistance training on NAFLD a randomized clinical trial. *Journal of Hepatology*. Sup. 2(56) 526-7.
18. **Zelber-Sagi, S.**, Toker, S., Shirom, A., Melamed, S., Berliner, S., Shapira, I., Halpern, Z., Santo, E., Shibolet O. (2012). Elevated alanine transaminase independently predicts new onset of depression in employees undergoing health screening examinations. *Hepatology*. Sup. 1(56) 1489.  
(The first and the second authors contributed equally to the paper)
19. **+Zelber-Sagi, S.**, Buch, A., Yeshua, H., Vaisman, N., Harari, G., kiss, O., Webb, M., Fliss, N., Halpern, Z., Santo, E., Oren, R., Shibolet, O. (2012). The effect of resistance training on NAFLD a randomized clinical trial. *American Journal of Gastroenterology*. Pages: 25. IF 7.282  
(The first and the second authors contributed equally to the paper)

## **I. Other Publications**

1. **Zelber-Sagi, S.**, Oren, R. Non alcoholic fatty liver the hepatic manifestation of the metabolic syndrome. *Israeli journal of medicine*. 8:25-30, 2007.
2. **Zelber-Sagi, S.**, Oren, R. Non alcoholic fatty liver disease. In: Liver diseases. Israel: *Prolog publishing* 2006.
3. **Zelber-Sagi, S.**, Yeshua H., Oren, R. Fatty liver and diabetes. In: The guide for the treatment of diabetes. Israel: *The National Diabetes Committee, Ministry of Health* 2012.
4. **Zelber-Sagi, S.**, Bugianesi, E., Newsome, P., Ratziu, V. Policy statement of the European Association for the Study of Liver Disease (EASL). Obesity is feeding the rise in Non-Alcoholic Fatty Liver Disease (NAFLD) across Europe. 2019. <https://easl.eu/wp-content/uploads/2019/04/EASL-Policy-statement-on-Food-obesity-and-Non-Alcoholic-Fatty-Liver-Disease.pdf>
5. United European Gastroenterology (UEG) association report. Nutrition and Chronic Digestive Diseases: An Action Plan for Europe. 2019. <https://ueg.eu/p/66#0>
6. **Zelber-Sagi, S.**, Sheron, N., Hydes, T. Food, alcohol, and obesity: Policy Statement on the coexistence of non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ARLD). 2020. [https://easl.eu/wp-content/uploads/2020/08/Full-version-Policy-Statement-on-the-coexistence-of-NAFLD-and-ARLD\\_26Aug2020.pdf](https://easl.eu/wp-content/uploads/2020/08/Full-version-Policy-Statement-on-the-coexistence-of-NAFLD-and-ARLD_26Aug2020.pdf)

7. United European Gastroenterology (UEG) association policy statement. Ultra-processed foods: an EU health crisis. Addressing unhealthy dietary patterns through mandatory front-of-pack labelling. 2020.  
<https://ueg.eu/files/1288/0e9fa1f3e9e66792401a6972d477dcc3.pdf>
8. COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. Peck-Radosavljevic M, Burra P, Ferret MB, Fracasso P, Ricciardiello L, Seufferlein T, Van Hooft P, van Leerdam M, **Zelber-Sagi S**; UEG Public Affairs Committee. United European Gastroenterol J. 2021. doi: 10.1002/ueg2.12173.